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ABSTRACT 
The pediatric mental health burden in the United States (US) is substantial, 
with more than 4 million children meeting diagnostic criteria for a mental health 
disorder.  As of 2014, this number represented 20% of US children and adolescents.  
In 2010, mental health disorders are estimated to cost children and their families $247 
billion dollars annually and severely impact quality of life for children and their 
families. From 2007 to 2010, inpatient admissions for mental health disorders in 
pediatric patients increased 24% and mood disorder admissions in pediatric patients 
increased 80% from 1997-2010.  An estimated $11.6 billion was spent on pediatric 
mental health hospitalizations from 2006 through 2011, with public sources such as 
Medicaid and Medicare responsible for approximately 50% of the payments, leaving 
50% to private payers.  This economic and clinical concern has led pediatric medical 
associations and health quality agencies to increase support and funding for pediatric 
mental health research and treatment.   
Medication therapy is a common intervention in mental health treatment and 
atypical antipsychotics are increasing in utilization, often becoming first-line therapy.  
Despite available data describing the need to treat pediatric mental health conditions, 
the available evidence for clinical effectiveness and economic impact of atypical 
antipsychotics (AAPs) has many shortfalls.  Most available research is derived from 
patients utilizing publicly-funded medical care, such as Medicaid or Medicare 
resources, with little data available about patients with privately-funded care.  To help 
address this gap in the literature, we used a large, privately-insured, US population for 
our analysis.  We examined if the increased trend in AAP utilization from previous 
  
 
research is also present in this pediatric population. Considering the payer perspective, 
we evaluated the cost of AAP medication therapy based on most recent utilization.   
Available studies lack information about the direct costs of pediatric mental 
health treatment and efficacy of psychiatric medications in the pediatric population.  
Most efficacy studies are based on clinical trials necessary for pediatric indication 
approval from regulatory agencies such as the Food and Drug Administration (FDA).   
Many of the AAP medications do not have pediatric clinical trial evidence available 
and are frequently utilized without pediatric indications. The available data suggests 
that off-label prescribing is not an uncommon practice in the pediatric patient 
population.3,4   
Approximately half of atypical antipsychotics do not have pediatric indications 
but are increasingly used, particularly in treating behavior disorders, due to such 
factors as improved patient compliance and improved side effect profiles.  Limited 
formal studies examining atypical antipsychotic use compared to other agents in the 
class have been conducted.  Studies with direct comparisons have yet to be conducted 
in the pediatric population with mental health disorders.   
The manuscripts that comprise this dissertation aim to provide new insights 
into available trend and utilization patterns of atypical antipsychotic medication use in 
children.  This research characterized the prevalence of atypical antipsychotic use in 
pediatric patient with mental health conditions in a large, privately insured US 
population, evaluating the diagnoses associated with treatment and estimate the cost of 
AAP medication therapy in this population.  This research determined if the trends 
observed in publicly-insured children persist in the privately-insured, pediatric patient.  
  
 
The analysis evaluated annual trends in prevalent use of atypical antipsychotic 
medication over 6-year period in this pediatric population and evaluated the 
appropriate use of AAPs for mental health diagnoses.  Lastly, an evaluation 
determined if specific antipsychotic therapy delayed time to readmission among 
privately-insured children following a psychiatric hospital admission.  The results of 
this dissertation will provide new insights regarding the trends and direct medication 
costs of atypical antipsychotic agents when utilized in pediatric patients with mental 
health disorders.   
Manuscript 1:  This analysis focused on characterizing the most recent (2015) 
AAP use in the pediatric population with mental health disorders, using a large, US 
population of privately- insured children.  The study evaluated if the prevalence data 
observed among publicly insured children persists.  Characterization of the prescribing 
trends for atypical antipsychotics and the medication costs of the use in this population 
were examined. Patterns of use across demographics and associated mental health 
diagnoses were characterized by the class of medication.  This study focused on the 
prevalent use of AAPs in pediatric patients with a mental health diagnosis, evaluated 
the mental health diagnoses associated with AAPs and the direct cost burden of 
medication therapy associated with this use of AAP in the pediatric population to the 
private payer. 
Manuscript 2:  This research evaluated the trends in the prescribing of atypical 
antipsychotic medications from 2010 through 2015 in this privately-insured pediatric 
population.  The trends of AAP use in the pediatric population over six years were 
examined.  The associated mental health diagnoses corresponding with AAP 
  
 
prescribing were described to examine the off-label diagnoses treatment prevalence in 
this population.  This study hypothesizes that the prevalent use of AAPs is increasing 
in the privately-insured patients and off-label prescribing accounts for most clinical 
use in pediatric patients.    
Manuscript 3:  This analysis examined pediatric patients who utilized oral 
atypical antipsychotic therapy after an inpatient admission for mental health treatment.  
Readmission for mental health treatment was evaluated to determine the efficacy of 
using oral AAP medications in pediatric mental health patients.  Some oral AAP 
agents have shown benefit in pediatric patients compared to placebo and have an 
official FDA indication for pediatric use.  Many clinical providers believe that this 
entire class of medications can demonstrate benefit in pediatric patients, regardless of 
FDA indication.  This study hypothesized that certain oral AAP medications are 
associated with delayed readmission in pediatric patients with an index admission for 
mental health treatment.
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PREFACE 
For this dissertation, a manuscript format will be utilized and will be comprised 
of three manuscripts, which examined (1) the current utilization and costs of atypical 
antipsychotic use in pediatric patients with mental health diagnoses, (2) the trend in 
atypical antipsychotic prescribing in the pediatric population and off-label prescribing 
of these agents, (3) the effectiveness of oral atypical antipsychotic agents in delaying 
inpatient readmission for mental health treatment in pediatric patients. 
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1.1 Abstract 
BACKGROUND:  Atypical antipsychotics (AAPs) are one of the most commonly 
prescribed classes of medication in the United States, representing 5% of all 
prescriptions among both pediatric and adult populations in 2012.  The overall use of 
AAPs in pediatric patients with mental health disorders has been increasing over the 
last 20 years.  Since 2007, almost double the number of AAPs have been approved on 
the US market and utilized in the pediatric population.1  However, most available 
utilization studies are dated with the most recent completed almost ten years ago.  The 
pediatric mental health burden in the United States (US) is substantial, with more than 
4 million children meeting diagnostic criteria for a mental health disorder.  As of 
2014, this number represented 20% of US children.   In 2010, mental health disorders 
are estimated to cost youth and families $247 billion. This study aims to provide a 
current (2015) assessment of atypical antipsychotic use in pediatric patients. 
OBJECTIVE:  This study will determine the prevalence and costs of atypical 
antipsychotic medication therapy in the privately-insured pediatric patient population 
with a mental health disorders.  This study will also identify patient and clinical 
characteristics that influence the use of atypical antipsychotic medication in pediatric 
patients with mental health diagnoses. 
METHODS:  Healthcare claims data extracted from the Optum Clinformatics ® Data 
Mart; (OptumInsight, Eden Prairie, MN) database between January 2015 and 
December 2015 were analyzed.  Children and adolescents (2-17 years) with a mental 
health diagnosis of interest, regardless of the presence of a paid claim for an atypical 
antipsychotic medication, were included.  Baseline characteristics of patients by AAP 
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medication use (received AAP medications anytime during the year versus none 
during the year) were determined and prevalence of AAP use was calculated.  
Predictors of AAP medication use were evaluated using a logistic regression model.  
Twelve-month average costs for AAP therapy was calculated for the AAP medication 
cohort using a linear regression model.   
RESULTS:  The one-year prevalence in the privately-insured, pediatric population 
with a mental health disorder was 7% (67.5 per 1,000 children) in 2015.  Despite 
being selected for inclusion in the cohort by mental health diagnosis of interest, we 
found that 29% of children treated with AAP medications did not have a mental health 
diagnosis at associated medical visit.  Specialty providers were responsible for 41% of 
the AAP prescribing and found that primary care providers only prescribed 17% of the 
AAP paid claims.  In the cost analysis, the average per member per month (PMPM) 
cost for the entire study population was $311.58. The total 12-month spend for 35,311 
paid claims for AAP medication therapy was $12.5 million in 2015, representing 
5,253 unique patients over the study period. Formulation of aripiprazole (generic and 
name brand) were the most commonly prescribed atypical antipsychotic medication 
(42%) followed by generic risperidone (25%) in 2015. The median cost of a paid 
claim for generic risperidone was $21.04 (Q1 = $12.39, Q3 = $31.55) per claim, 
representing almost the lowest cost per claim of all the AAP agents.  The median cost 
of a paid claim for generic aripiprazole was $531.23 (Q1 = $519.79, Q3 = $668.89) 
per claim, representing the highest cost per paid claim compared with all other 
available generic AAP agents. 
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CONCLUSIONS:  The prevalence of using atypical antipsychotic medications in 
pediatric patients with mental health disorders is significant in the privately-insured 
population.  Individual costs vary greatly by AAP medication and further costs studies 
are warranted to determine the potential economic impact to a specific private payer.
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1.2  Introduction 
The pediatric mental health burden in the United States (US) is substantial, 
with more than 4 million children meeting diagnostic criteria for a mental health 
disorder.2–4  As of 2014, this number represented 20% of US children.  Pediatric 
patients are defined as children from 2 to 12 years and adolescents from 13 to 18 
years.5 In 2010, mental health disorders are estimated to cost youth and families $247 
billion dollars annually and severely impact quality of life for children and their 
families.2–4,6   An estimated $11.6 billion was spent on pediatric mental health 
hospitalizations from 2006 through 2011, with public sources such as Medicaid and 
Medicare responsible for approximately 50% of the payments, leaving 50% to private 
payers.7  This economic and clinical concern has led pediatric medical associations 
and health quality agencies to increase support and funding for pediatric mental health 
research and treatment.2,7  
Antipsychotic medication therapy is the gold standard of treatment for 
psychosis and related behavior disorders in adult patients.  In the past decade, these 
medications have gained popularity as treatments for psychiatric and behavior 
disorders in adolescents (13-<18 years old) and pediatric patients (2-<13 years old), 
despite gaps in clinical efficacy and safety research.8–10  Pediatric patients with 
behavioral and affective disorders, autism-spectrum disorders and mood disorders 
often benefit from pharmacotherapy with antipsychotic agents in conjunction with 
other nonpharmacological interventions.10–13  While not all atypical antipsychotics 
have an Food and Drug Administration (FDA) indication for use in pediatric patients, 
atypical antipsychotics are considered first line agents by mental health experts and 
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clinicians, compared to typical antipsychotic medications, due to improved side effect 
and safety profiles, as demonstrated in adult clinical trials. 13 A Cochrane review of 
atypical antipsychotics in patients under the age of 18 years found only 13 suitable 
randomized, controlled trials appropriate for inclusion, representing 1,100 pediatric 
patients in total.14 There is a lack of sufficient evidence regarding the comparative 
effectiveness of atypical agents over traditional agents in pediatric patients.14  AAP 
medications offer the possibility of benefit in pediatric patients; however, there is 
limited evidence to support widespread use of these agents. 
As of 2012, AAPs are one of the most commonly prescribed classes of 
medication in the United States, representing 5% of all prescriptions among both 
pediatric and adult populations and over $13 billion in drug expenditures.13  The 
overall trend of use for AAP in pediatric patients with mental health disorders has 
been increasing over the last 20 years.  From 1995 to 2002, multiple studies 
demonstrated a 5-fold increase of antipsychotic use in pediatric and adolescent 
patients in the United States.14,15  This trend was largely due to the increased 
availability of atypical antipsychotics and the common misconception that atypical 
antipsychotics demonstrated lower risk of serious adverse events.16,17   From 2007 to 
2010, a study evaluating off-label use of AAP medications, found that 12% of 
outpatient medical visits documented the use of AAPs.  This utilization study was 
based on medical visits where AAP medications were documented and not on paid 
claims data.  More recent trend data utilizing administrative claims data in privately-
insured children is unavailable.  Cooper et al examined antipsychotic mediation use in 
publicly-insured youth and found that 53% of incident users were being treated for 
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mood or behavior disorders and not traditional psychiatric conditions.8,15,16,18  
Utilization and medication costs can vary over time based on market changes.  Since 
2007, almost double the number of AAPs have been approved on the US market and 
have been utilized in the pediatric population, according to claims database analyses.1  
However, most available measures of prevalent use are somewhat dated with the most 
recent completed studies analyzing data only as recent as 2011.12  
Medication therapy is a common intervention in mental health treatment and 
atypical antipsychotics are increasing in use and often a first-line therapy.3,7,9  Despite 
available data describing the need to treat pediatric mental health conditions, the 
available evidence for clinical effectiveness and economic impact of atypical 
antipsychotics (AAPs) has many shortfalls.  As of 2010, most of the trend studies 
focused on publicly-insured children, such as Medicaid enrollees, with few studies 
including large, privately-insured populations.  The available data suggests a growing 
trend in atypical antipsychotic use in pediatric patients with mental health diagnoses, 
but only a limited number of studies evaluated use of this medication class among 
privately-insured patients.  It is unclear whether the available prevalence of AAP use 
among publicly insured children is also comparable to that among privately-insured 
pediatric populations with mental health diagnoses.8,16,18,19   
The goal of this study is to characterize AAP use in the pediatric population 
with mental health diagnoses, using a large, US population of privately-insured 
children. Characterization of the prescribing prevalence for atypical antipsychotics and 
the medication costs of the use in this population will be examined. Examining this 
population for changes in prescribing over the most recent year can provide additional 
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insight into spending trends and changes in payer spending for AAP therapy.  This 
study will evaluate how new market entries and new generic medications have 
possibly changed the spending profile and may provide additional data on the 
medication costs differences seen in this study compared to available literature.  
Patterns of use across demographics and associated mental health diagnoses will be 
described to better characterize the use of this class of medication in the pediatric 
population with mental health diagnoses.  Considering the payer perspective, we 
evaluated the direct cost burden of AAP medication therapy for 2015, the most recent 
year of available data. We evaluated the overall utilization of these medications among 
privately-insured pediatric patients with mental health diagnoses. We discuss a 
comparison of the overall utilization observed in our study to available reported 
utilization among publicly-insured children.   
1.3 Methods 
Data Source and Study Design 
This cross-sectional study was conducted utilizing administrative data (Optum 
Clinformatics ® Data Mart; OptumInsight, Eden Prairie, MN) for the period of 
January 1, 2015 to December 31, 2015.  This data includes commercial health 
insurance claims (inpatient and outpatient medical records, laboratory data, facility 
information, and outpatient pharmacy) and enrollment data from large, private insurer 
across the United States.20  This dataset provides healthcare information on 36 million 
beneficiaries and encompasses 1.2 billion individual medical records.   
Sample selection  
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We conducted a cross-sectional study of atypical antipsychotic use among US 
pediatric enrollees to describe the use of atypical antipsychotic medication as most 
recently prescribed during the calendar year 2015.  Our analyses were conducted using 
pharmacy claims data, outpatient medical claims data and patient eligibility data, 
which included patient age, gender, geographic region. Pharmacy claims data included 
medication information such as days’ supply, quantity, prescribing physician and cost 
data.  Outpatient medical visit provided clinical information on date of service, 
diagnosis codes at time of visit and provider type. Figure 1 displays a flowchart of 
inclusion and exclusion criteria.  Each patient was required to have at least one 
medical record present in 2015 with a mental health diagnosis of interest and 
information was aggregated to patient level (Appendix A).  There were 87,503 
pediatric patients with at least one mental health diagnosis enrolled in dataset in 2015.  
Pediatric patients (ages 2-17 years) represented 10% of the population available for 
analysis in administrative database.   Before exclusion criteria were applied, 23% 
(20,732) of patients had a diagnosis of Disruptive or Aggressive Behavior (DAB) 
Disorders, 14% (11,870) had a diagnosis of Anxiety Disorders and 13% (11,611) had 
a diagnosis of Developmental Disorders (Table 1).  Of the entire original cohort, 0.3% 
(210) of patients had a diagnosis of six mental health diagnostic categories 
documented at a medical visit claim during 2015. 
Patients were excluded from study for the following conditions: 18 years or 
older during study period, did not have continuous enrollment during study period or 
incomplete information available for paid claims or medical visits for analysis.   All 
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available dosage forms and atypical antipsychotic medications were included in the 
analysis, regardless of indicated use for the pediatric population.  
Outcomes 
For determination of atypical antipsychotic prescription use, the most recent 
dispensing of this medication type was used.   Patients were identified as having an 
AAP medication paid claim using National Drug Codes (NDCs) as provided in 
Appendix B, for an available AAP medications on the US market.  If patients had 
more than one paid claim for an AAP, we selected the most recent paid claim (latest 
fill date in 2015) to represent the paid claim of interest to best represent the most 
relevant clinical treatment plan.    
For the cost analysis, the total cost of AAP medication therapy was determined 
as a summation of all paid claims for AAP medications for individual pediatric 
patients with mental health diagnoses over the calendar year 2015.  To determine the 
12-month average spend for atypical antipsychotic medication therapy, a per-member 
per-month (PMPM) variable was determined based on patient’s overall days of 
exposure to AAP medication therapy and total cost of AAP therapy for each patient.  
The PMPM was calculated by totaling the cost for all paid claims for a given patients 
and dividing by total day supply of AAP medication therapy.  This value was then 
multiplied by 30 days to represent the monthly cost associated with AAP medication 
therapy for each patient.  This value provides a mean cost per patient for all AAP 
medications received per month, regardless of number of claims represented.    
Statistical Analysis 
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The prevalence of AAP use was examined by age group (2 to 5 years, 6 to 12 
years, 13 to 17 years), gender, geographic region (Northeast, Midwest, West and 
South), primary mental health diagnosis closest to the AAP paid claim date 
(Appendix A), provider category and concomitant medication use, including 
anxiolytics, antidepressants, antiepileptics and stimulants.  Concomitant medication 
therapy was defined as the presence of a paid claim for the medication class of interest 
during the study period of 2015.  This study focused on overall utilization of atypical 
antipsychotics and did not examine therapy switching between agents or overlap of 
multiple AAPs because this information is not needed to characterize the current 
utilization of any AAP agent.  Mental health diagnoses were treated as a categorical 
variable, with an indicator variable for each condition as listed in Appendix A, using 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-
9-CM) and Tenth Revision (ICD-10-CM) diagnostic codes. Several studies examining 
mental health ICD-9 codes for research have been performed and indicate strong 
validity in using these codes in claims data mental health research.21,22  Davis et. al 
found a positive predictive value (PPV) of 76% for mental health condition in 
administrative claims data.22  Several previous research groups used these diagnostic 
categories for administrative data analysis of pediatric mental health conditions.9,15,22 
To determine the diagnosis associated with a specific AAP paid claim, a 60-day 
window (60 days before and after) around the date of prescription fill was established 
and the closest medical visit was selected to ascertain the diagnoses.  If the 60 days 
window fell outside the study period, then patients were excluded for not having 
sufficient data for complete analysis.  For patients that received no AAP therapy in 
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2015, the diagnoses from the most recent medical provider visits in 2015 were used.  
Per medical visit, only the first ten fields were used because these captured 95% of 
available diagnosis information in the database.   
Among pediatric patients with mental health diagnoses, we determined the 
frequency and percentage of patients with AAP use compared to those without AAP 
therapy in 2015.  Differences in patient characteristics and prescription claim 
information between the two groups were determined using the Chi-Square test. 
Prevalence was calculated as the number of pediatric patients with mental health 
diagnoses receiving a pharmacy dispensing for at least one AAP medication divided 
by the total number of children with a mental health diagnosis of interest during 2015.  
A logistic regression model was used to determine the factors associated with the use 
of AAP medication therapy. All pairwise interactions between covariates were tested 
and none were found to be statistically significant. No interaction terms were included 
in the final model due to lack of statistical significance.  Collinearity between 
independent variables was tested using Variance Inflation Factors (VIF) test and no 
significant collinearity was found.  No adjustments for collinearity were made in the 
final model.  We evaluated the associations in both unadjusted and adjusted models 
that also included gender, age, geographical region, concomitant medication uses and 
provider specialty.  Covariates with a P value < 0.20 in the univariate model were 
included in the final adjusted model, with primary mental health diagnosis forced into 
the model due to known clinical relevance for AAP therapy use.   
The direct cost burden of medication therapy for pediatric patients with mental 
health conditions was analyzed as a percentage of the total spend for pediatric patients 
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with mental health disorders of interest over the study period. To assess the 12-month 
average cost for AAP medication therapy per patient, the PMPM variable was chosen, 
to represent the most accurate average cost per plan member from the payer 
perspective. A generalized linear model was used to evaluate patient or prescription 
level variables that were associated with PMPM spending.  Each patient included had 
least one paid claim for an AAP during 2015.  Patients with multiple claims in a given 
month had all claim costs for AAP medications totaled for each month, then the total 
days exposed per patient were determined.  Patients with multiple claims for AAP 
medications were aggregated to one PMPM cost per month for analysis.  PMPM was 
calculated as the total cost per month divided by the total days exposed per month 
multiplied by thirty days.  Total days exposed to AAP therapy was determined by 
summing up the days’ supply of all paid claims in a given month per patient.  The 
PMPM variable was assessed for normality using a histogram and measures of skew.  
The distribution appeared to be non-normal, with a skewness 1.11 indicating a long 
right skewed tail and kurtosis value 2.1.23–25 A modified park test was performed to 
determine the distribution for the cost model.25,26  Test statistics revealed coefficient 
near two (lambda=1.76), which provides evidence the outcome to be modeled as a  
gamma distribution. A log-link with the gamma distribution fit better than other link 
options  (log-link AIC=69,436, identity link AIC=69,448, logit link AIC=120,939)  
and was the model employed in the final analysis.26 All statistical tests were two-sided 
and performed at a 0.05 significance level and conducted using SAS Enterprise Guide 
Version 7.1 (Cary, North Carolina, USA). 
1.4 Results 
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Table 1 provides overall mental health diagnoses of the original pediatric 
cohort from 2015 prior to exclusion criteria, regardless of AAP medication therapy 
presence.  In the original patient database of pediatric patients in 2015, 87,503 
pediatric patients had a mental health diagnosis of interest in a medical recording 
during 2015.  Before exclusion criteria were applied, 23% (20,732) of patients had a 
diagnosis of Disruptive or Aggressive Behavior (DAB) Disorders, 14% (11,870) had a 
diagnosis of Anxiety Disorders and 13% (11,611) had a diagnosis of Developmental 
Disorders.  Of the entire original pediatric cohort, 0.3% (210) of patients had a 
diagnosis of six mental health diagnostic categories documented at a medical visit 
claim during 2015.  This population included 71,630 children with mental health 
diagnoses of interest recorded in their medical claims in 2015 and continuous 
eligibility for all of 2015.  The mean age of the entire study population was 11.7 
(standard deviation [SD]=4.1) years.  Of the entire population, 63% were male (P 
value <0.001). A total of 4,833 (6.8%; 95% CI=6.6, 6.9) patients received at least one 
paid claim for an AAP medication in 2015.   The prevalence of atypical antipsychotic 
medication use was 67.5 per 1000 pediatric patients with mental health diagnosis of 
interest.   
We found that 1,378 (29%) of the 4,833 pediatric patients receiving AAP 
medication therapy did not have a psychiatric diagnosis of interest at the associated 
medical appointment (+ 60 days around AAP claim) during the study period (Table 
2). In patients receiving an AAP paid claim, across the entire study period, the leading 
diagnostic category present was 1336 children with Mood disorders (28%).  Children 
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with Disruptive or Aggressive Behavior (DAB) Disorders were next frequent with 842 
(17%) children.  
Several patient characteristics varied between those who received AAP 
medications and those who did not (Table 2). Patients receiving AAP medications 
were on average 2.1 years older than those receiving no AAP medication therapy. 
Adolescents (age 13-17 years) received the most paid claims for AAP therapy (69%) 
compared to children aged 6-12 years (30%) and 2-5 years (1%) (P value<0.001). The 
distribution of region was comparable between the two groups.  Concomitant 
medication therapy with stimulant, antiepileptic, antidepressant and anxiolytic 
medications was significantly different between the two groups.  Children receiving 
AAP medication therapy had increased rates of concomitant use of stimulants (9% vs 
8%, P value<0.001)), antiepileptics (2% vs. 1%, P value<0.001), antidepressants (7% 
vs. 4%, P value <0.001)) and anxiolytics (4% vs. 1%, P value<0.001) when compared 
to children receiving no AAP medication therapy.   Category of mental health 
diagnosis of interest was significantly different between the patients receiving AAP 
medication therapy and those that did not, with most patients in both groups having no 
associated mental health diagnosis at most recent medical visit or associated with AAP 
medication paid claim.  Significantly more pediatric patients reported an anxiety 
disorder as primary mental health diagnosis in the AAP medication group than in the 
no AAP therapy group (12% vs. 6%, P value <0.001).  Similarly, in pediatric patients 
receiving AAP therapy, mood disorders were reported as the primary mental health 
diagnosis (28% vs. 3%, P value <0.001) in significantly more cases, than in patients 
with no AAP therapy.  The prevalence of AAP use compared across patient 
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characteristics is displayed below in Figure 2.  This figure presents the prevalence of 
characteristics in children with mental health diagnoses of interest, prescribed AAP 
medication therapy among the entire study population of children included in the 
analysis (N =71,630). The number of patients from the study cohort with that given 
characteristic that are included in the denominator, are listed at the top of the column.  
All patients included in this figure had a mental health diagnosis of interest during 
2015, continuous eligibility during the study period and a medical visit associated with 
a paid AAP claim or medical visit available for analysis. 
Results from the unadjusted and adjusted logistic regression models are 
displayed in Table 3. In the unadjusted model, several patient characteristics were 
found to have significant differences in AAP prescribing among children with mental 
health diagnoses of interest.  Female children had 20% increased odds of being 
prescribed AAPs than male children (odds ratio (OR) = 1.2; 95% confidence interval 
(CI) = 1.1, 1.2). Children of an older age were 20% more likely (OR=1.2; 95% 
CI=1.1, 1.2) to have a paid claim for AAPs.  In the unadjusted model, children aged 6-
12 years of age were 9.8 times more likely to be prescribed AAPs than children aged 
2-5 years (OR=9.8; 95% CI=7.2, 13).  Adolescents (ages 13-17) were 19 times more 
likely to have a paid claim for AAP therapy (OR=19.0; 95% CI=14.0, 26.0).  Patients 
in the Midwest (OR=1.3; 95% CI=1.1, 1.4) and the South (OR=1.2; CI=1.1, 1.3) 
regions of the US were significantly more likely to receive AAP therapy, compared to 
subjects in the Northeast region.  Patients with a documented Mood Disorder 
diagnosis were 5 times more likely to receive an AAP paid claim (OR=23.0; CI=4.6, 
5.8), compared to those with psychotic disorders as the primary mental health 
 17 
 
diagnosis.  Patients with a documented mental health disorder in the “Other” category 
were 2.8 times more likely to be prescribed AAPs (OR=2.8; 95% CI=2.2, 3.5) 
compared to patients with a Psychotic Disorder documented.  Patients with 
documented Anxiety Disorder were 20% increased odds of having an AAP paid claim 
(OR=1.2; 95% CI=1.1, 1.4) compared to children with documented psychotic 
disorders.  If the patient’s primary mental health diagnosis was for an DAB or 
Developmental Disorder, the pediatric patient had 30% increased odds of having an 
AAP paid claim (OR=1.3; 95% CI=1.1, 1.4), (OR=1.3; 95% CI=1.1, 1.6), compared to 
patients with a Psychotic Disorder documented. 
Concomitant use of several relevant medication classes was evaluated for 
significance as predictors of receiving AAP medication therapy. In the unadjusted 
model, a paid claim for stimulant medication during 2015 indicated 20% increased 
odds of receiving AAP medication therapy (OR=1.2; 95% CI=1.1, 1.3).  Concomitant 
use of antidepressants in 2015 predicted 60% increased odds of being prescribed AAP 
therapy (OR=1.6; 95% CI=1.4, 1.8).  The use of antiepileptic medications in pediatric 
patients with mental health diagnoses predicted they were 4 times more likely to be 
prescribed an AAP medication (OR=4.0; 95% CI=3.2, 5.1).  Patients with a paid claim 
for anxiolytic medication in 2015 were 2.8 times more likely to also receive an AAP 
medication (OR=2.8; 95% CI=2.4, 3.3) during study period.  Provider specialty was 
also evaluated as a clinically relevant predictor of AAP medication use.  Patients seen 
by a specialty provider (psychiatrist) had 5 times the increased odds of receiving an 
AAP medication compared to patients seen by a primary care provider (OR=5.0; 95% 
CI=4.5, 5.3).  Similarly, pediatric patients with a mental health disorder seen by a 
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specialist had 13 times increased odds of receiving a paid claim for AAP therapy than 
patients seen by a non-physician mental health provider (OR=12.5; 95% CI=11.0, 
14.0).   
In the adjusted final model, female pediatric patients with mental health 
diagnoses of interest had 11% decreased odds (adjusted odds ratio (aOR)=0.89; 95% 
CI=0.83, 0.95) of having a paid claim for AAP medication therapy.  In the final 
model, age was a significant predictor in the prescribing of AAP medication, with a 
one-year increase in age having an associated 10% increased odds of receiving a paid 
claim for an AAP (aOR=1.1; 95%CI=1.0, 1.1).  After adjusting for other patient and 
clinical characteristics, children 6-12 years of age were 10 times more likely than 
younger children to be prescribed AAP medication therapy, (aOR=10.3; 95% CI=7.5, 
14.1).  Adolescent patients with a mental health diagnosis of interest were 16 times 
more likely to receive AAP medication therapy, when compared to children ages 2-5 
years (aOR=16.7; 95% CI= 12.2, 22.9).   In the final model, patients with a mood 
disorder were 2 times more likely to receive an AAP medication, compared to patients 
with a documented Psychotic Disorder (aOR=2.2; 95% CI=2.0, 2.6).  Also, patients 
with documented Developmental (aOR=1.4; 95% CI=1.2, 1.7) had a 40% increased 
odds and patients with documented Other Disorders (aOR=1.6; 95% CI=1.2, 2.0) had 
60% increased odds of receiving an AAP, compared to pediatric patients with 
documented Psychotic Disorders.  Patients with a documented Anxiety Disorder had 
37% decreased odds of receiving a paid claim for an AAP (aOR=0.63; 95% CI=0.55, 
0.73) compared to patients with a documented Psychotic Disorder.  In the adjusted 
model, patients with DAB Disorders had 29% decreased odds of having a paid claim 
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for an AAP (aOR=0.71; 95% CI=0.62, 0.82) compared to patients with a documented 
Psychotic Disorder.  Finally, adjusting for other covariates, patients with no mental 
health disorder documented had 80% decreased odds of receiving a paid claim for an 
AAP (aOR=0.20; 95% CI=0.18, 0.23) compared to a documented Psychotic Disorder.  
Once adjusting for other covariates, pediatric patients with concomitant use of 
stimulant medications had 48% decreased odds of being prescribed AAP medication 
therapy (aOR=0.52; 95% CI=0.46, 0.58) in the final adjusted model.  Similarly, 
patients with concomitant antidepressant use had 55% decreased odds of being 
prescribed AAP medications (aOR=0.45; 95% CI=0.39, 0.50).   After adjusting for 
other covariates, the use of antiepileptic medications during 2015 predicted 50% 
increased odds of having a paid claim for AAP medication during the study period 
(aOR=1.5; 95% CI=1.2, 2.0).   After adjusting for other covariates, pediatric patients 
with mental health disorders demonstrating anxiolytic use during the study period no 
longer had a significant effect on likelihood of receiving an AAP paid claims.   
Overall, demonstrated use of other psychotropic medication classes were significant 
predictors in the prescribing or not prescribing of AAP medication therapy.  Of note, 
in the adjusted model, several variable associations changed directions when adjusted 
for other covariates.  In the adjusted model, female gender, use of stimulants and use 
of antidepressants were associated with a reduced risk of AAP use, which was a 
change from an increased risk in their respective univariate models. By adding one 
variable to the model at time, we determined that these estimates changed direction 
after adjustment for age group.  This indicates that the age group of the patient at time 
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of paid claim demonstrates some unmeasured confounding affecting the other 
covariates, that is independent of the direct interaction of the variables. 
In the adjusted model, prescriber specialty was a significant predictor for AAP 
prescribing. Patients seen by a specialty provider had 2.5 times the increased odds of 
receiving a paid claim for AAP medication than patients seen by a primary care 
provider (aOR=2.5; 95% CI=2.3, 2.7).  Patients seen by a specialist had 5 times the 
increased odds of receiving an AAP medication paid claim than children seen by a 
non-physician mental health professional (psychiatric nurse practitioner, physician 
assistant) (aOR= 5.0; 95% CI=4.5, 5.6).  After adjusting for other patient 
characteristics, region was no longer a statistically significant predictor of AAP 
prescribing in the final model.    
Cost Model for AAP Medications Use in Pediatric Patients 
The total 2015 annual expenditure for AAP prescriptions in the pediatric 
population with mental health conditions was estimated at $12,487,066.71, in a large 
US private payer.  This expenditure represented 35,311 paid claims for AAP 
medication therapy and 5,253 unique patients over the study period.  This 
corresponded to an average spending of $1.04 million per month for AAP medication 
in pediatric patients with mental health conditions for the private insurance plan. The 
average and median per-member-per-month (PMPM) costs of AAP medication 
therapy was $311.58 (standard deviation [SD]=$327.16) and $169.06 (quartile 1 to 
quartile 3 [Q1,Q3] = $$19.62, $556.32), respectively. The 12-month average AAP 
medication cost per patient was $3738.96 (SD=$3925.92).    
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The median cost per paid claim in 2015 is displayed by medication in Table 4.  
Generic risperidone was the most commonly prescribed atypical antipsychotic 
medication (25%) followed by generic aripiprazole (22%) and name brand Abilify® 
(20.0%). The median cost of a paid claim for generic risperidone was $21.04 
(Q1=$12.39, Q3=$31.55) per claim, representing almost the lowest cost per claim of 
all the AAP agents.  The median cost of a paid claim for name brand aripiprazole was 
$978.86 (Q1=$978.86, Q3=$978.86) per claim, representing the highest cost per paid 
claim compared with all other available AAP agents.  
The cost data was then analyzed using a generalized linear model (GLM) to 
determine any covariates that were a significant predictor of PMPM costs.  Table 5 
presents the results of the log-gamma regression of the per-member per-month 
(PMPM) costs during the 12-month study period adjusted for patient demographics.  
Using a gamma regression model with an identity link function, age group, gender, 
mental health diagnostic category and provider specialty were statistically significant 
predictors of total annual expenditure for AAP medication therapy.  Children aged 6-
12 years had overall adjusted mean spending for AAPs that was $90.22 (95% CI=-
$14.40, $155.45) higher than patients aged 2-5 years.  This corresponds with a PMPM 
that was 50% (adjusted odds ratio (aOR)=1.5; 95% CI=0.97, 2.1) higher than children 
aged 2-5 years.  Adolescents aged 13-17 years had overall adjusted mean spending for 
AAPs that was $116.62 (95% CI=$12.48, $180.63) higher than patients aged 2-5 
years.  This corresponds with PMPM costs that were 60% higher (aOR=1.6, 95% 
CI=1.1; 2.3) than children aged 2-5 years.  Older patients often require higher doses of 
medication therapy or more frequent administration and these dosing regimens often 
 22 
 
cost more.  Female subjects had overall adjusted mean spending for AAPs that was 
$30.69 (95% CI= $7.36, $54.67) higher than male subjects.  Female gender 
represented a PMPM cost that was 10% (aOR=1.1;95% CI=1.0, 1.2) higher than male 
subjects.  The adjusted difference in mean spending for AAPs between subjects from 
different US regions was only significant comparing patients located in the South to 
the Northeast.  Pediatric patients located in the South region of the US had overall 
adjusted mean spending on AAPs that was $38.89 (95% CI= $0.78, $73.93) higher 
than patients in the Northeast US.  This represented overall PMPM costs that were 
10% (aOR=1.1; 95%CI=1.0, 1.3) higher than children located in the Northeast region.  
1.5 Discussion 
In privately-insured children and adolescents, the prevalence of atypical 
antipsychotic medication therapy was 67.5 per 1000 patients (6.75%; 95% CI=6.6%, 
6.9%) with a mental health diagnosis of interest present in 2015.  In our study, gender 
was associated with differences in prescribing AAP therapy, which aligned with 
previous research in private- and publicly-insured children.11,15,27  These previous 
studies found that patients of male gender had increased odds of receiving AAP 
medication therapy.  Our study found similar increased odds in male patients.  The 
children receiving AAP therapy were significantly older (13.6 vs. 11.8 years) and 
older age was an important predictor of a patient receiving AAP therapy.   
In our analysis, the 2015 prevalence of atypical antipsychotic use was higher 
than determined in previously studied research of privately-insured children and 
adolescents across the US.15  Previous studies have found that publicly-insured youth 
have consistently lower AAP prevalence to that found in our study, at 1.9% in 2005 
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and 1.7% in 2010.11  Since 2005, the AAP medication therapy options have doubled, 
as AAP medication approvals have increased dramatically in the US.  Furthermore, 
previous studies in publicly insured population included all children, not only children 
with mental health diagnoses present in medical records for their analysis. 8,11,19   
Including all children in the analysis could increase the population that is considered at 
risk for AAP medication use, leading to a possible underestimation of the proportion 
of study participants that received AAP medication therapy. These differences in study 
population could explain some of these observed differences.  Private insurance payers 
have different formulary practices than public payer systems.  Formulary approval and 
reimbursement practices could change the utilization and diversity of a medication 
class and represent the difference between our study and the results from studies 
analyzing publicly funded patients.  Combination therapy with multiple AAP 
medications or therapy switching was not examined in this analysis.   Combination 
therapy or medication switching is common in mental health treatment 
recommendations and represents a future direction that should be explored. Future 
research should also examine overlapping medication classes with AAP therapy or 
switching therapy to AAP as a significant factor in AAP medication use in pediatric 
patient with mental health diagnoses. 
Our study found that 29% of pediatric patients treated with an atypical 
antipsychotic have no mental health diagnosis in an associated claim for medical visit 
within 60 days of the paid prescription claim.  Figure 2 shows the overall distribution 
of mental health diagnosis in the pediatric patients that supported their inclusion in the 
original study cohort.  Among pediatric patients with a mental health diagnosis 
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present, Developmental disorders (13%), Anxiety Disorders (14%) and Disruptive or 
Aggressive Behavior (DAB) disorders (23%) were the leading diagnoses associated 
with AAP medication therapy.  In the original database of pediatric patients with 
mental health diagnoses during calendar year 2015 (Figure 1), 0.3% (210 patients) of 
pediatric patients had all six mental health diagnostic categories present at a medical 
visit during the study period.  The absences of mental health diagnoses in the 
associated medical visit around the paid claim for AAP medication therapy could be 
explained by the lack of coding in the medical visit for continued medication treatment 
by the visit provider. Lohr et al. analyzed AAP use in Kentucky Medicaid patients and 
found that 72% of subjects analyzed were missing a diagnostic code associated with 
paid claim and this issue was only resolved after 2006 once Medicaid rules required an 
appropriate code before paid claim would be fulfilled.10  Other previous trend studies 
in public- and privately-insured pediatric patients categorized missing diagnoses as 
“other” or excluded patients with no diagnosis available completely.8,28  The rate of 
missing mental health diagnosis found in our study was lower than previously 
published literature.  A 2015 study found no mental health diagnosis present at an 
associated medication visit in 60% of pediatric patients treated with AAPs.12  Previous 
research also found that in 75% of cases, all children with MH diagnoses of interest 
treated with AAP medications has multiple psychiatric diagnoses.15  Similarly, we 
found that in the original cohort, 44% of children had multiple mental health 
diagnoses present during the study period. 
We found that specialty providers were the leading prescribers (41%) 
associated with paid claims for AAP therapy.  Olfson et al.12 noted that specialists 
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were the provider associated with AAP therapy in approximately 69% of paid claims 
in 2010.  The differences in associated prescriber characteristics could be related to 
coding differences between private insurers and their claims process.  Prescribing 
physician requirements can differ between private and public payers.  Formulary 
requirements for certain payers require specialist prescribing for certain populations or 
medication classes that may not be required of practices in our privatively-insured 
population.  
Concomitant medication therapy was a significant predictor of a pediatric 
patient receiving AAP therapy.  Use of stimulant and anxiolytic medications reduced 
the likelihood of a patient receiving a fill of an AAP medication in 2015.  Sikirica et 
al. previously explored ADHD patients receiving stimulant therapy and the likelihood 
of receiving AAP medication therapy.12  Their study identified 8.3% of stimulant 
treated children receiving an AAP in the 12-month study period.13  Our study found a 
similar rate of concomitant use of stimulants with AAP medication therapy.  Olfson et 
al. explored the overall rate of concomitant use of anxiolytics and antidepressants with 
antipsychotic medication treatment.9  Their study found much higher rates of 
antidepressant use (33.7%) and anxiolytic use (9.7%) in patients on AAP medication 
therapy, than was identified in our current study.  This previous analysis was based on 
medical office visits documenting the medication of interest and not based on 
individual paid claims for the relevant medication class.  This methodology could 
explain the increased rates of concomitant use found in their study compared to results 
presented here.  In this previous study, it is unclear if the patient was receiving the 
medication or the provider only discussed the medication therapy during the office 
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visit.  The use of antidepressant and stimulant medications when analyzed alone, 
seemed to be a significant predictor of AAP use.  However, in the adjusted model 
concomitant use of these two classes of medications showed lower odds of predicting 
use of AAP medications.  This might indicate that some confounding is present and 
the other significant variables (age, gender, region, mental health diagnosis, provider 
specialty) are confounders for concomitant use of antidepressants and stimulants and 
their effect on AAP prescribing.   
Our study is one of the first to describe the 12-month average medication cost 
of AAP therapy in the privately-insured pediatric patient population.  The total 12-
month cost burden for 35,311 paid claims for AAP medication therapy was $12.5 
million in 2015, representing 5,253 unique patients over the study period.  The 
average per-member per-month (PMPM) cost for the entire study population was 
$311.58.  This study found that aripiprazole (name brand and generic) was the most 
commonly prescribed AAP medication in privately insured youth, with 44% of paid 
claims.  Olfson and collegues12 described risperidone as the most common AAP agent 
used in privately insured youth in 2010.  This difference in choice of agents is most 
likely related to the pediatric indications granted by the FDA for aripiprazole and its 
dosage forms in 2009 and the availability of a generic formulation in 2015.29   
In 2015, we estimated that $12.5 million was spent on atypical antipsychotic 
medication therapy among this privately-insured pediatric population.  In a similar 
study of children enrolled in Florida Medicaid, researchers found that in Fiscal Year 
2005 (FY2005) , $151 million was spent on AAP medication therapy. 30 This drastic 
difference compared to our study findings can most likely be explained by the peak 
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utilization that was seen for AAP medication therapy in 2005 and lack of generic 
formulations available on the US market.  Their study adjusted dollar spending 
amounts to align with the medical care component of the consumer price index for the 
region during the FY2005.30  Our study took direct costs paid by the payer from 
prescription claims data. Most of the available cost research focuses on publicly-
insured children and our study is one of the first to explore the direct medication costs 
to a private, national payer.  In 2004, the FDA issued advisory committee findings that 
recommended more conservative use of atypical antipsychotics in children and Pamer 
et. al examined a corresponding decrease in AAP medication use.28,31  This research 
group observed a decline in AAP medication prescribing, but this decline did not 
achieve statistical significance nor did they examine overall spending or changes in 
average cost.31  In 2016, Wang et al. performed a time-trend analysis examining AAP 
medication prescribing before and after supplemental pediatric indications being 
granted by the FDA.  They found no statistically significant changes in AAP 
medication prescribing with the additional approved pediatric indications.28   These 
studies provide limited evidence that the FDA medication safety alert and other 
prescribing decisions might have altered antipsychotic medication prescribing.  Future 
studies that compare time trend utilization data against major clinical guideline 
recommendations or new FDA indications for AAP medications in larger population 
could provide stronger evidence of these influence of these administrative actions on 
prescribing habits. 
1.6 Limitations 
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The analysis was conducted using insurance claims data; therefore, limited 
clinical information was available for patients that were included in the final analyses.  
Clinical information from claims data is limited to available medical documentation 
presented in the visit record as recorded by the documenting provider.  Physical 
assessment information about the patient and laboratory information was limited and 
not included in the analysis. A mental health diagnosis of interest was not present in 
the medical visits associated with index AAP paid claim in 29% of the patients 
receiving AAP medication therapy.  Prior studies have demonstrated the validity of 
ICD-9 codes for accurately representing a mental health diagnosis in the medical 
record.21,22  However, other prevalence studies have found a similar rate of an absence 
mental health diagnosis associated with medication use.  The window around the 
index claim for AAP therapy was expanded from +/- 30 days to +/- 60 days; however, 
this did not improve the capturing of diagnostic information from medical visits.  This 
rate of incomplete mental health diagnosis documentation could make it difficult to 
interpret the proper clinical indication for AAP medication use.  Miscoding in the 
practical setting could lead to variations in the results and make analysis by clinical 
disorder difficult to interpret.  Furthermore, the observed study period may not have 
captured the incident mental health event for a patient, so we could be observing 
patients well after their initial diagnosis. The cost portion of this analysis only 
discussed the direct medication costs to the private healthcare plan and did not address 
other economic costs, such as utilization of other treatment resources, cost to 
caregivers and parents and lost school or work time.  Finally, the prevalence and cost 
analyses both use the paid claim as the basis for evaluation.  For concomitant 
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medication therapy and its significance as a predictive variable, only paid claims 
during study period was examined.   
1.7 Conclusion 
The prevalence of using atypical antipsychotic medications in pediatric patients 
with mental health disorders is significant in the privately insured population. The 
prevalence in the privately insured population was 6.75% (CI=6.6%, 6.9%) or 67.4 per 
1000 children with mental health disorders in 2015.  The total yearly spending by the 
private payer for atypical antipsychotic medications in pediatric patients was $12.5 
million dollars in 2015. This represented an average per-member per-month cost of 
$311.58 for atypical antipsychotic medication therapy in pediatric patients with mental 
health diagnoses of interest.  Individual costs vary greatly by AAP medication and 
further costs studies are warranted to determine the potential economic impact to a 
specific private payer.  This study represents the most recent calendar year available 
for analysis.  
Overlap or switching of therapy to or from AAP medication therapy was not 
examined but could be evaluated in future studies.  Combination therapy with other 
AAP medications or other psychotropic medications is a common clinical practice and 
the possible impact on AAP utilization should be examined.  Validation studies of the 
ICD-9 codes use for mental health diagnoses in the outpatient medical record warrant 
additional validation studies.  Validation studies available are specific for claims data 
research in adults with mental health disorders.  Providers may believe a stigma exists 
in documenting mental health conditions in the pediatric population and diagnostic 
code analysis may not be as reliable.  These studies could provide additional insight in 
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to the use of diagnostic codes and the predictive value in mental health epidemiologic 
studies.  Further studies about updated utilization and spending are needed to examine 
how more recent FDA decisions and safety alerts may have altered AAP prescribing 
and medication class utilization. 
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Figure 1: Selection of Patients for Analyses of Prevalence of Atypical Antipsychotic Medication 
Utilization and Cost of Atypical Antipsychotic Medication Therapy in Pediatric Patients (2 to 17 
years) (2015). 
(Optum Clinformatics ® Data Mart; OPTUMInsight, Eden Prairie, MN) 
 
87,503 Pediatric patients (age 2-
17 years) with at least one 
mental health diagnosis of 
interest (2015) 
   
71,630 Pediatric patients with 
continuous eligibility for all of 
2015   
• study population for 
prevalence of AAP 
medication use 
 
 
15,873 patients excluded 
due to non-continuous 
eligibility during study 
period 
898,293 All patients with mental 
health diagnosis of interest in 
2015 
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patients (age > 18 years) with 
mental health diagnoses of 
interest in 2015 
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AAPs in eligible children 
in 2015 
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for cost study  
 
 
 
66,797 Pediatric patients with 
no paid claim for AAP 
medication therapy in 2015 
and available medical records 
5,253 Individual pediatric 
patients with at least one paid 
claim for AAP medication 
during 2015  
 
 
4,833 Individual patients 
with paid claim for AAP and 
available medical records  
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Table 1.  Distribution of Mental Health Diagnoses in all Pediatric Patients (2 to17 years) 
Available in Study Cohort during 2015. * 
(Optum Clinformatics ® Data Mart; OPTUMInsight, Eden Prairie, MN) 
 
 
*No exclusion criteria applied.  All pediatric patients with at least one MH diagnosis included in original cohort. 
Primary MH Diagnosis of Interest All children (N, %) with 
Mental Health Diagnosis  
(N= 87,503) 
Disruptive or Aggressive Behavior Disorder 20732 (23) 
Anxiety Disorder 11870 (14) 
Developmental Disorder 11611 (13) 
Three MH Disorders present 10192 (12) 
Anxiety and Secondary MH Disorder 10187 (12) 
Developmental Disorder with Secondary MH Disorder 6846 (8) 
Disruptive and Aggressive Behavior with Secondary MH Disorder 2935 (3) 
Mood and secondary MH Disorder 4087 (5) 
Four MH Disorders Present 2929 (3) 
Mood Disorder 2798 (3) 
Psychotic Disorder 1315 (2) 
Other Mental Health Disorder 1181 (1) 
Five Mental Health Disorders Present 454 (0.5) 
Six Mental Health Disorders Present 210 (0.3) 
Psychotic Disorder with Secondary MH Disorder 156(0.2) 
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Table 2.  Demographic and Clinical Characteristics of Privately-Insured, US Children (2 to 17 
years) with Mental Health Diagnoses of Interest during 2015 by AAP status (N =71,630) 
 (Optum Clinformatics  ® Data Mart; OptumInsight, Eden Prairie, MN) 
 
*comparisons in baseline characteristics between children receiving AAPs and those that did not 
during study period using Chi-Squared tests or t-tests as appropriate. 
 
 Children with an 
AAP paid claim 
(N=4,833) 
Children with no 
AAP Treatment 
(N=66,797) 
P value* 
 
Patient Age, Years, Mean+ SD 13.7 (3.0) 11.6 (4.2) <0.001 
Age Group (years) n(%)   <0.001 
2-5 years (pre-school) 41 (0.9) 7525 (11.3)  
6-12 years  1439 (29.8) 26921 (37.6)  
13-17 years (adolescents) 3353 (69.4) 32351 (48.4)  
Patient Gender, n (%) <0.001 
Male 2891 (59.8) 42166 (63.1)  
Female 1942 (40.2) 24631(36.9)  
Patient Region, n (%) <0.001 
Northeast 523 (10.8) 8300 (12.4)  
Midwest 1609 (33.3) 20278 (30.4)  
South 1953 (40.4) 26763 (40.1)  
West 748 (15.5) 11456 (17.2)  
MH Diagnosis Category, n (%) <0.001 
Anxiety Disorder 571 (11.8) 3884 (5.8)  
Mood Disorders 1336 (27.6) 2183 (3.3)  
Disruptive or Aggressive Behavior 
Disorders 
842 (17.4) 5581 (8.4)  
Developmental Disorders 169 (3.5) 1072 (1.6)  
Psychotic Disorders 417 (8.6) 3510 (5.3)  
Other MH Disorders 120 (2.5) 366 (0.6)  
No MH Diagnosis Present 1378 (28.5) 50201 (75)  
Use of Antiepileptics, n (%) <0.001 
Yes 92 (1.9) 319 (0.5)  
No 4741 (98.1) 66478 (99.5)  
Use of Antidepressants, n (%) <0.001 
Y 312 (6.5) 2817 (4.2)  
N 4521 (93.5) 63980 (95.8)  
Use of Anxiolytics, n (%) <0.001 
Y 181 (3.8) 922 (1.4)  
N 4652 (96.2) 65875 (98.6)  
Use of Stimulants, n (%) <0.001 
Y 444 (9.2) 5174 (7.8)  
N 4389 (90.8) 61623 (92.2)  
Provider Specialty, n (%) <0.001 
Acute Care Hospital 154 (3.2) 4332 (6.5)  
Mental Health Professional (non-
physician) 
578 (11.9) 3198 (4.8)  
Outpatient Facility 209 (4.3) 2361 (3.5)  
Primary Care Provider 810 (16.8) 14843(22.2)  
Specialist 2003 (41.4) 7416 (11.1)  
Therapy Provider (Social Worker, 
Psychologist) 
384 (8.0) 3026 (4.5)  
Other Non-Physician Provider 695 (14.4) 31621 (47.3)  
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Figure 2. Prevalence of Privately-Insured Children (2 to 17 years) with Mental Health Disorders 
in the US Receiving AAP Medication Therapy in 2015 by Patient and Clinical Characteristics (n 
=71,630).*  
 
 
*Number of children present in study cohort with given covariate listed at top of column (denominator) 
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Table 3.  Unadjusted and Adjusted Odds Ratios (ORs) with 95% Confidence Intervals (CIs) 
Based on a Logistic Regression Model for Patient and Clinical Factors Associated with Atypical 
Antipsychotic Medication Prescribing among US Privately-Insured Pediatric Patients (2 to 17 
years) in 2015 (N=4,833). 
 
 Unadjusted Adjusted* 
ORs (95% CIs) P value ORs (95% CIs) P value 
Patient Age 1.2 (1.1, 1.2) <0.001 1.1 (1.1, 1.1) <0.001 
Age Group (years)   <0.001  <0.001 
2-5 years Reference    
6-12 years 9.80 (7.20, 13.0)  10.3 (7.5, 14.1)  
13-17 years (adolescents) 19.0 (14.0, 26.0)  16.7 (12.2, 22.9)  
Gender   <0.001 <0.001  
Female 1.20 (1.10, 1.2)  0.89 (0.83, 0.95)  
Male Reference  
Region  <0.001  0.075 
Midwest 1.3 (1.1, 1.4)  1.1 (1.0, 1.3)  
South 1.2 (1.1, 1.3)  1.1 (1.0, 1.3)  
West 1.0 (0.9, 1.2)  1.0 (0.9, 1.1)  
Northeast Reference 
Mental Health Diagnosis  <0.001  <0.001 
Anxiety Disorders 1.2 (1.1, 1.4)  0.63 (0.55, 0.73)  
Mood Disorders 5.2 (4.6, 5.8)  2.2 (2.0, 2.6)  
Disruptive or Aggressive Behavior 
Disorders (DAB) 
1.3 (1.1, 1.4)  0.71 (0.62, 0.82)  
Developmental Disorders 1.3 (1.1, 1.6)  1.4 (1.2, 1.7)  
Psychotic Disorders Reference     
Other MH Disorders 2.8 (2.2, 3.5)  1.6 (1.2, 2.0)  
No MH Diagnosis Present 0.23 (0.21, 0.26)  0.20 (0.18, 0.23) 
Provider Category  <0.001  <0.001 
Acute Care Hospital 0.13 (0.11, 0.16)  0.19 (0.16, 0.23)  
Mental Health Professional (non-
physician) 
0.67 (0.61, 0.74)  0.42 (0.38, 0.47)  
Outpatient Facility 0.33 (0.28, 0.38)  0.68 (0.58, 0.81)  
Primary Care Provider 0.20 (0.19, 0.22)  0.40 (0.36, 0.43)  
Specialty Provider Reference 
Therapy Provider (Social Worker, 
Psychologist) 
0.47 (0.42, 0.53)  0.41 (0.4, 0.5)  
Other non-physician provider 0.08 (0.07, 0.09)  0.20 (0.2, 0.2)  
Use of Stimulants   
Yes 1.2 (1.1, 1.3) 0.003 0.52 (0.5, 0.6) <0.001 
No Reference 
Use of Anxiolytics  
Yes 2.8 (2.4, 3.3) <0.001 1.2 (1.0, 1.4) 0.12 
No Reference 
Use of Antidepressants  
Yes 1.6 (1.4, 1.8) <0.001 0.45 (0.4, 0.5) <0.001 
No Reference 
Use of Antiepileptics  
Yes 4.0 (3.2, 5.1) <0.001 1.5 (1.2, 2.0) 0.002 
No Reference 
*adjusted for the following covariates at baseline: age group, gender, US region, Mental Health 
Diagnosis, Provider Category, Concomitant use of stimulants, anxiolytics, antidepressants and 
antiepileptics. 
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Table 4. Median Costs (US Dollars) per paid claim and Total Spending for Atypical Antipsychotic 
Therapy for Privately-Insured, US Children (2 to 17 years) with Mental Health Disorders during 
2015 (N=5,253 patients with 35,311 paid claims).  
Medication Name Number of Paid 
Claims (%) 
Median (Q1, Q3) * Total Spending in 
2015, $ (% of yearly 
total) 
Abilify (name brand) 7,094 (20) 978.86 (978.86, 978.86) 5,621,429.06 (45) 
Aripiprazole (generic) 7,664 (22) 531.23 (519.79, 668.89) 4,614,370.15 (37) 
Clozapine 307 (0.9) 46.57 (23.93, 121.66) 24,095.85 (0.2) 
Fanapt 84 (0.2) 635.67 (317.84, 635.67) 41,647.13 (0.3) 
Geodon (name brand) 34 (0.1) 635.94 (476.96, 771.74) 19,814.11 (0.2) 
Invega (name brand) 406 (1.1) 665.48 (665.48, 998.22) 334,147.95 (2.7) 
Latuda 1123 (3.2) 638.68 (638.68, 638.68) 758,792.30 (6.1) 
Olanzapine (generic) 1624 (4.6) 23.89 (19.60, 33.16) 48,637.88 (0.4) 
Olanzapine ODT 134 (0.4) 211.74 (112.06, 420.31) 38,568.81 (0.3) 
Palperidone ER 79 (0.2) 641.99 (610.96, 800.97) 55,694.41 (0.5) 
Quetiapine Fumarate 
(generic) 
5343 (15) 19.50 (9.55, 32.37) 148,893.23 (1.2) 
Risperdal (name brand) 42 (0.1) 613.91 (511.59, 1367.94) 31,340.74 (0.3) 
Risperdal M-TAB 11 (0.03) 704.93 (704.93, 704.93) 7,754.23 (0.1) 
Risperidone (generic) 8814 (25) 21.04 (12.39, 31.55) 241,841.20 (1.9) 
Risperidone ODT (generic) 229 (0.7) 182.15 (95.89, 335.34) 51,671.77 (0.4) 
Saphris 309 (0.9) 345.69 (345.69, 691.37) 155,686.00 (1.3) 
Ziprasidone HCL (generic) 2010 (5.7) 96.92 (44.55, 197.64) 290,796.45 (2.3) 
Zyprexa (brand name) 4 (0.01) 471.36 (471.36, 471.36) 1885.44 (0.02) 
Total Yearly Spending for AAP Medication Therapy                                                    
$12,487,066.71 
*Quartile 1 (Q1) and Quartile 3(Q3) representing first and third quartiles for median value 
 
 
 40 
 
Table 5.  Cost Ratios and Mean Cost Differences (US Dollars) with 95% Confidence Intervals 
(CIs) Based on a Gamma Generalized Linear Regression Model of Per-Member Per-Month 
(PMPM) Costs for AAP Medication Therapy in Pediatric Patients (2 to 17 years) with Mental 
Health Diagnoses of Interest in United States, 2015 (N=5,253 patients with 35,311 paid claims) 
 
Independent 
Variable 
 Unadjusted Modelb Adjusted Modelb,c 
 Mean Cost 
Difference, $a,  
(95% CI) 
Cost Ratio 95% CIs P-value Cost 
Ratio 
95% CIs P-value 
Intercept 173.01 (102.52, 280.59) 
Age Group  
2-5 years  Reference Reference Reference 
6-12 years 90.22 (-14.40, 155.45) 5.8 5.7, 5.8 <0.001 1.5 0.97, 2.1 0.05 
13-17 years 116.62 (12.48, 180.63) 5.3 4.9, 5.7 <0.001 1.6 1.1, 2.3 0.02 
Gender  
Male Reference Reference Reference 
Female 30.69 (7.36, 54.67) 5.8 5.7, 5.9 <0.001 1.1 1.0, 1.2 0.01 
Region  
Northeast Reference Reference Reference 
Midwest 12.45 (-26.00, 47.97) 5.7 5.7, 5.8 <0.001 1.0 0.92, 1.2 0.56 
South 38.89 (0.78, 73.93) 5.8 5.7, 5.9 <0.001 1.1 1.0, 1.3 0.04 
West 20.66 (-45.54, 95.96) 5.7 5.6, 5.8 <0.001 1.0 0.86, 1.1 0.86 
a Unadjusted and adjusted mean costs per patient was estimated using the identity link function  
bUnadjusted and Adjusted coefficients of gamma regression were estimated using the log link function and are 
reported as a ratio of average per member per month (pmpm) costs. 
cThe following covariates were adjusted for in the final model: age group, gender and US region. 
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2.1 Abstract 
BACKGROUND:  The overall trend of use for AAP in pediatric patients with mental 
health disorders has increased over the last 20 years.  From 1995 to 2002, multiple 
studies demonstrated a 5-fold increase of antipsychotic use in pediatric and adolescent 
patients in the United States.1–3 This treatment is often “off-label” or not for a specific 
Food and Drug Administration (FDA)-approved condition in children or 
adolescents.1,2,4,5  Furthermore, 20% of pediatric patients prescribed an atypical 
antipsychotic medication had no FDA approved diagnosis associated with treatment.6 
As of 2010, most of the trend studies focused on publicly-insured children, such as 
Medicaid enrollees, with few studies evaluating large, privately-insured populations.  
The available studies suggest a growing trend in atypical antipsychotic use in pediatric 
patients, but only limited studies evaluated this medication class use in privately-
insured patients.   
OBJECTIVE:  This study identified the trend in atypical antipsychotic medication 
prescribing in pediatric patients from 2010 to 2015.  It also determined the rate of off-
label prescribing by diagnosis of AAP medications in the same study population. 
METHODS:  An administrative dataset (Optum Clinformatics ® Data Mart; 
OptumInsight, Eden Prairie, MN) containing prescription claims between 2010 and 
2015 was examined for all children 2 to 17 years of age who had a documented paid 
claim for an atypical antipsychotic medication.  Patient demographic and clinical 
characteristics were analyzed using descriptive statistics.  A generalized estimating 
equation (GEE) model with Poisson variance and a log-link was used to determine any 
demographic or clinical characteristics that predicted atypical antipsychotic use.  To 
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characterize off-label diagnostic prescribing, a GEE model with a binomial variance 
and a log-link was employed to evaluate patient and clinical factors as predictors of 
off-label use in pediatric patients. 
RESULTS:  A total of 378,007 paid claims were evaluated, representing 40,750 
individual patients aged 2 to 17 years old.  The use of atypical antipsychotics within 
the entire pediatric population increased over the study period from 0.19% in 2010 to 
0.28% in 2015.  The rate of AAP paid claims per year for pediatric patients slightly 
increased with each calendar year: 57% in 2011, 63% in 2012, 79% in 2013, 73% in 
2014.  In 2015, pediatric patients had a 270% increase in the yearly rate of claim count 
per year during the study period (Rate Ratio (RR)=2.7; 95% confidence interval (CI) 
=2.6, 2.9), compared to 2010.   Female patients had 10% reduction in the rate of paid 
AAP claims, compared to males (RR=0.90; 95% CI=0.89, 0.92).  Our study found that 
both children 2-5 years old and children 6-12 years old had a 20% increase in the rate 
of paid AAP claims over the study period, compared to older children 13-17 years old 
(RR=1.2; 95% CI=1.1, 1.2; RR=1.2; 95% CI=1.1, 1.2).   
Off-label prescribing by diagnosis of AAP medications represented 62% (95% 
CI=62%, 63%) of the paid claims evaluated.  Children 2-5 years old were 43% less 
likely to be prescribed atypical antipsychotics for off-label diagnoses (adjusted odds 
ratio (aOR)=0.57, 95% CI =0.37, 0.90) than children 13-17 years old.  Children 6-12 
years old were 10% less likely (aOR = 0.90; 95% CI=0.77, 1.0) than adolescents (age 
13-17 years) to be prescribed atypical antipsychotics for off-label indications. Female 
pediatric patients were 1.2 times more likely to be prescribed an AAP in an off-label 
manner (aOR=1.2; 95%CI=1.1, 1.3) compared to male children.     
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 CONCLUSION:  The use of atypical antipsychotic in children 2-17 years old 
increased overall from 2010 to 2015.  This increase could be attributed to more 
atypical antipsychotic medications available in the US market.  Over the study period, 
the number of AAP agents approved by the FDA increased substantially, from 7 
agents to 13 available on the US pharmaceutical market. The practice of off-label 
prescribing by diagnosis is prevalent in the pediatric population, despite the lack of 
formal indications for pediatric use in this medication class. 
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2.2. Introduction 
The overall trend of use for AAP in pediatric patients with mental health 
disorders has increased over the last 20 years.  From 1995 to 2002, multiple studies 
demonstrated a 5-fold increase of antipsychotic use in pediatric and adolescent 
patients in the United States.1–3  This increase was largely due to the increased 
availability of atypical antipsychotics and the common misconception that atypical 
antipsychotics demonstrated lower risk of serious adverse events.7,8 Cooper et al 
examined antipsychotic mediation use in publicly-insured youth and found that 53% 
of incident users were being treated for mood or behavior disorders, rather than 
traditional psychiatric conditions.1,4,7,9  This treatment is often “off-label” or not for a 
specific FDA-approved condition in children or adolescents.1,2,4,5  Furthermore, 20% 
of pediatric patients prescribed an atypical antipsychotic medication had no FDA 
approved diagnosis associated with treatment.6 The medications of interest and the 
corresponding FDA approval are listed in Appendix B.10  As of 2010, most of the 
trend studies focused on publicly-insured children, such as Medicaid enrollees, with 
few studies including large, privately-insured populations.  The available data suggests 
a growing trend in atypical antipsychotic use in pediatric patients; however, there have 
been few studies that evaluated this medication class use in privately-insured patients.  
More data in privately-insured children is unavailable and evaluation of the trend 
among  privately-insured children has not been characterized nor compared to a 
population of publicly-insured children.4,5,7,9,11  This study evaluated the overall 
utilization of these medications among privately-insured pediatric patients and 
discussed comparisons to publicly-insured children. 
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Clinical and demographic characteristics of youth receiving atypical 
antipsychotic medications are not fully understood.  Available analyses of commercial 
and Medicaid prescription claims indicated that AAP treatment was significantly more 
common in boys than girls.5,9,12,13  According to several state Medicaid studies, 
treatment of mood disorders, attention-deficit/hyperactivity disorder or disruptive and 
aggressive behavior disorders accounted for the majority of antipsychotic use.4,5,14  
One sample population of psychiatric outpatient visits found 77% of children had no 
diagnosis of any psychotic disorder associated with AAP medication therapy.15  The 
data for commercial or privately-insured patients is limited and there remains 
uncertainty  if the finding for publicly-insured children persists in  the privately-
insured population. 
Utilization and medication costs can vary over time based on market changes.  
Since 2007, there has been a doubling in the number of AAPs approved on the US 
market with demonstrated use in the pediatric population.10  However, most available 
measures of prevalent use are somewhat dated and based on data from before 2009.  
The increasing off-label use of medications, including AAPs, has been criticized and 
contested in legal cases, leading to changes in recommendations for such use by the 
FDA in 2009.  Studies highlighting the off-label use of AAPs in the elderly has drawn 
criticism and concern, leading to Medicaid earning reimbursement for spending for 
off-label prescribing.16,17 Policy makers anticipate similar off-label utilization in the 
pediatric population.   The proportion of prescriptions authorized for off-label use in 
pediatric patients has not yet been evaluated in the privately-insured population. 
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Prior research that indicated increased use of atypical antipsychotic medication 
in children, coupled with the potential increase in off-label use, have led to public and 
professional uncertainty regarding recommended treatment regimens.  The goal of this 
study was to evaluate annual trends in prevalent use of AAP medication over 6-year 
period from 2010 to 2015 in a large, privately-insured pediatric population and 
evaluate the appropriate use of AAPs for a given mental health diagnoses.  
Appropriate use was determined by labeled FDA indications for AAP medication 
referenced in the paid claim.  We hypothesized that AAP medication utilization 
increased over the 6-year available study period and off-label prescribing of AAP 
medication represented the predominant use in pediatric patients.   
2.3 Methods 
This retrospective cohort study identified all paid prescription claims for AAP 
medications used in pediatric patients from 2010 through 2015.  For each calendar 
year of the study period, patients were identified that were 2 to <18 years of age (as of 
the start of the year) and filled at least 1 prescription for an AAP agent during the year.  
We reported the number of patients who used any AAP overall and stratified by 
specific AAP agents.  The utilization of AAPs was quantified as the prevalence of 
AAPs use; that is, the proportion of the pediatric population on AAPs during each 
year.  Incidence of AAP therapy was also evaluated at the first year of follow-up to 
assess patients newly prescribed.  All pediatric patients present for analysis in the 
administrative database (Optum Clinformatics ® Data Mart; OptumInsight, Eden 
Prairie, MN) were considered in the prevalence calculation.  
Data Source and Study Design 
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This retrospective longitudinal study used the commercial data set (Optum 
Clinformatics ® Data Mart; OptumInsight, Eden Prairie, MN) from January 2010 to 
December 2015.  This data includes commercial health insurance claims (inpatient and 
outpatient medical records, laboratory data, facility information, and outpatient 
pharmacy) and enrollment data from large, private insurer across the United States.18  
This dataset provides healthcare information on 36 million beneficiaries and 
encompasses 1.2 billion individual medical records.   
Sample Selection 
Patients aged 2 to 17 years of aged (at the start of the year with paid claim) that 
had a paid claim for an atypical antipsychotic were included in the analysis.  Patients 
were then excluded if they lacked continuous eligibility during the claim year or did 
not have an associated medical visit in the time frame around the paid claim of 
interest.     Continuous eligibility was applied as exclusion criteria to ensure all 
prescriptions claims and medical visits were available for analysis.  Pediatric patients 
included in this analysis were not required to have continuous eligibility for the entire 
study period of six years, but only for year of paid AAP claim.  Over the study period 
from 2010 to 2015 , 43,120 pediatric patients got an AAP paid claim, representing 
490,123 paid claims.  The final study cohort included 40,750 pediatric patients 
(378,007 paid claims for AAPs) with mental health conditions. Medical claims were 
collected for all types of services and the diagnoses were coded with the International 
Classification of Diseases, 9th Revision and International Classification of Diseases 
10th revision—Clinical Modification (ICD-9-CM, ICD-10-CM).  Medical claims 
associated within a 60-day window of the atypical antipsychotic (AAP) paid claim 
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were used to identify associated ICD-9-CM and ICD-10-CM diagnoses (Appendix A) 
associated with the prescription.  For both analyses, patients and paid claims were 
excluded if they had no medical visit within the reference window (+ 60 days around 
fill date) to provide clinical information for analysis. Ten diagnosis fields were queried 
for the associated reason for the medical visit.  Medical visit data was carried forward 
for up to one year if it was missing at a particular medical visit.  A one-year follow-up 
was used to ascertain all relevant clinical information for patients that were likely to 
be stabilized on AAP medication therapy and no longer presented to a provider for 
monthly medication refills.  This ascertainment may explain repeated prescription paid 
claims for AAP medication therapy without a more recent medical appointment 
associated with the paid claim, since stable patients may be provided refills on an AAP 
prescription that do not require repeat monitoring by a provider.  Pharmacy claims 
were recorded for all outpatient pharmacy plan claims and were coded with National 
Drug Codes (NDCs), with detailed information that included medication name, fill 
data, days’ supply, quantity and drug strength.  All pediatric patients were included in 
this analysis regardless of presence of associated mental health diagnosis at the 
associated medical visit. 
Statistical Analysis 
Overall AAP use prevalence was presented as a proportion of the pediatric 
population with mental health diagnoses prescribed AAPs in the cohort in the given 
year (no. of users per 1,000 children).19  The total number of paid claims, unique 
patients and prevalence (represented as a percentage) is described in Table 1.  The 
total number of children available in dataset was determined by examining all patients 
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with at least one paid claim in each year for patients age 2 to 17 years.  The number of 
paid claims from 2010 to 2015 for AAP medication in pediatric patients were 
examined overall and by AAP medication (Figure 1).  Among patients with at least 
one AAP paid claim and an associated medical visit available for analysis, we 
determined the frequency and percentage of baseline patient and clinical 
characteristics (Table 2). 
We conducted a longitudinal analysis to evaluate the annual rates of AAP use, 
both overall and by medication class.  Total counts of AAP paid claims per year was 
determined per patient.  The unit of analysis for this section of the study was the 
medical visit for each patient associated with the AAP paid claim, which was then 
aggregated to a yearly count per patient.  We examined a yearly count to better capture 
any market changes that may affect AAP prescribing, such as new drug approvals and 
generic formulations.  Previous prescribing trends indicated that these market changes 
usually influence prescribing patterns over six to twelve months after the change is in 
effect.3,4,11,12   The outcome of interest was the count of AAP claims per patients in 
each year.  As mentioned above, 40,750 patients were included in the study cohort, 
representing 378,007 paid claims.  The yearly claim count variable was determined by 
summing the individual paid claims for AAP medications for a given patient for each 
year during the study period.  Mental health diagnosis associated with each paid claim 
was retained as the primary diagnosis for analysis unless a more recent paid claim was 
available with this information.  Similarly, the provider details and specialty 
information were retained for each patient until a newer paid claim occurred with up-
to-date information available.  
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Because there are multiple visits per patient, a generalized estimating equation 
(GEE) model was used to estimate the prevalence of children prescribed AAPs over 
time accounting for correlation within patient.20  A GEE model with Poisson variance 
and a log-link was used to evaluate the association of covariates with annual claim 
count of AAP paid claims per patient over the study period.20   No interaction terms 
were included in the final model due to lack of statistical significance of these terms.  
Collinearity between independent variables was tested using Variance Inflation 
Factors (VIF) test and no significant collinearity was found; thus, no adjustments for 
collinearity were made in the final model.  Covariates that had a P value < 0.20 in the 
unadjusted model were included in the final adjusted model.  No independent 
variables demonstrated a significant interaction with time over the study period, so no 
interactions with time were included in the final model.   
We assessed the prevalence of possible off-label diagnostic use of AAPs for 
the study period of 2010 to 2015 as a percentage of total AAP prescriptions during that 
period. The unit of analysis for off-label use by diagnosis was each patient that 
received a paid claim for an AAP medication. Patients contributed multiple claims to 
the analysis over the study period and correlation within patient was addressed.  To 
determine off-label diagnostic use, paid claims were only included if an associated 
medical visit of interest was found within the window mentioned above (+ 60 days).  
For paid claims that did not have enough time available in study period for complete 
analysis, the observation was excluded.  For the off-label diagnostic use analysis, 
74,841 paid claims (N=37,274patients) were included in the final cohort.  A 
descriptive analysis evaluated off-label by diagnosis use and results were presented as 
 52 
 
an overall percentage of off-label diagnostic use for each AAP medication.  Any 
presence of diagnosis associated with AAP use that is off-label by diagnosis during the 
study period was considered off-label use, regardless if other diagnoses for a patient 
are indicated.  Any use of clozapine (Clozaril), iloperidone (Fanapt) and ziprasidone 
(Geodon) was considered off-label diagnostic use in this patient population.  As of 
December 2017, none of these agents have earned a pediatric indication for use from 
the FDA.  Any off-label diagnostic prescribing was assessed for each paid claim and 
patient and provider characteristics associated with that claim were evaluated as 
predictors for off-label prescribing.  Off-label use can also include use of agents for 
unapproved age groups or at doses not approved by FDA indication.  For this analysis, 
possible off-label use was determined by diagnosis associated with AAP prescription.   
Because multiple paid claims per patient were present, a generalized estimating 
equation (GEE) model was used to estimate the prevalence of off-label prescribing by 
diagnosis of children prescribed AAPs over time, accounting for correlation within 
patient.20  A GEE model with binomial variance and a log link was used to evaluate 
the association of age, gender, region, provider category and associated mental health 
diagnosis as covariates for predicting the off-label diagnostic use of atypical 
antipsychotics in the study population.20   This model used a robust estimator of 
variance to account for correlation between visits within a patient.  No interaction 
terms were included in the final model due to lack of statistical significance of these 
terms.  Collinearity between independent variables was tested using Variance Inflation 
Factors (VIF) test and no significant collinearity was found; thus, no adjustments for 
collinearity were made in the final model.  Mental health diagnosis categories were 
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combined as follows due to low sample size in the original seven categories 
(Appendix A): Anxiety and Mood disorders; Developmental and Disruptive-
Aggressive Behavior Disorders; Psychotic, Other Disorders or No Mental Health 
Diagnosis present.  All covariates with P value < 0.20 were included in the adjusted 
model.  The final multivariable model was examined for fit using the Hosmer-
Lemeshow Goodness of Fit test, which indicated no evidence of a lack of fit (P value 
= 0.48).  All statistical tests were two-sided and performed at a 0.05 significance level 
and analyses were performed using SAS Enterprise Guide Version 7.1 (Cary, North 
Carolina, USA). 
2.4 Results 
Trends in Atypical Antipsychotic Prescribing  
From 2010 to 2015, there were 424,722 unique patients (ages 2 to 64 years) 
that received at least one atypical antipsychotic medications, with 4,647,014 paid 
claims for AAP medications over the entire study period.   There were 490,123 paid 
claims for AAPs identified representing 78,481 individual pediatric patients (age 2 to 
17 years) receiving at least one AAP paid claim over the study period.  This represents 
an average number of 11.3 paid claims for AAP medications per pediatric patients 
over the six-year period.   
In the final sample, 378,007 paid claims were evaluated, representing 40,750 
individual patients.  The use of atypical antipsychotics in this population increased 
over the years from 0.19% (2010) to 0.28% (2015).  This percentage is out of all 
eligible children present in the dataset during the study period.  Table 1 and Figure 1 
below outline the yearly AAP medication claim count over the study period.  
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A full description of baseline characteristics for the study population is 
presented in Table 2.  The mean age of pediatric patients receiving AAP therapy was 
12.7 years (SD=3.7) at time of paid claim.  Most patients (55%) were aged 13-17 
years or adolescents.  Specialty providers were the primary prescribers (40%) of AAP 
medication prescriptions.  Primary care providers were the second most frequent 
prescribers (20%) of AAP prescriptions.  At the medical visit associated with the AAP 
paid claims, 35% of patients did not have a mental health diagnosis present in the 
medical file.  With a mental health disorder associated with the AAP paid claim, 
Mood disorders were the most common mental health diagnosis (28%), with 
Disruptive or Aggressive Behavior disorders the second most common (14%).    
Based on the GEE model among the aggregated annual data, the rate ratios of 
claim count are presented in Table 3. The final adjusted model demonstrated that 
time, gender, age group, region and mental health diagnosis all demonstrated a 
significant effect on the rate of paid claims for AAP medications over time in years.  
Calendar time was found to have a significant association with the rate of pediatric 
patients receiving a paid claim for AAP medications over the study period.  With 2010 
(baseline) set as the reference point, pediatric patients had a 60% increase rate of claim 
count in 2011 (RR=1.6; 95% CI=1.5, 1.7).  As the study period progresses, the rate of 
AAP paid claims per pediatric patient slightly increased with each calendar year 63% 
in 2012, 79% in 2013, 73% in 2014.  In 2015, pediatric patients had a 270% increase 
in the rate of claim count compared to 2010 (RR=2.7; 95% CI=2.6, 2.9).    
Female patients had 10% lower rates of paid AAP claims over the study period 
(RR=0.90; 95%CI=0.89, 0.92).  Children 2-5 years of age had a 20% increased rate 
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(RR=1.2; 95%CI=1.1, 1.2) of paid AAP claims over the study period and children 6-
12 years of age also had a 20% increased rate (RR=1.2; 95% CI=1.1, 1.2) compared to 
children 13-17 years old.  
Geographic location of the pediatric patient has a small influence on the rate of 
paid claims over the study period.  Patients living in the Northeast US were found to 
have a 4% increase in the rate of AAP paid claims (RR=1.04; 95% CI=1.0, 1.1) and 
patients located in the Midwest had a 3% increase rate (RR=1.03; 95% CI=1.0, 1.1) 
when compared to patients living in the western US. Overall, region of the US that 
patients were located did not have a significant effect on the rate of atypical 
antipsychotic prescribing over the study period (P value =0.13). 
Mental health diagnosis associated with paid claims had a significant effect on 
the rate of AAP paid claims over the study period (P value <0.001).  All comparisons 
were made to patients that had no mental health diagnosis associated an AAP paid 
claims.  Patients with an Anxiety Disorder had 14% lower rate of AAP paid claims 
over the study period (RR=0.86; 95% CI=0.83, 0.89).  Patients with Mood disorders 
were found to have a 9% lower rate of AAP paid claims and Disruptive or Aggressive 
Behavior (DAB) Disorders were found to have 6% lower rate of AAP paid claims 
compared to patients with no present mental health diagnosis (RR=0.91; 95% 
CI=0.89, 0.93 and RR=0.94; 95% CI=0.91, 0.97, respectively).    Patients with 
“Other” mental health diagnoses (Tourette’s Syndrome, Eating Disorders) had a 21% 
lower rate of paid claims for AAP medications during the study period (RR=0.79; 
95% CI=0.75, 0.82) compared to patients with no present mental health diagnosis.  
Patients with developmental disorders and psychotic disorders did not have a 
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significantly different rate of paid claims for AAP medications over the study period, 
when compared to patients with no mental health diagnosis. Overall, the category of 
prescribing provider responsible for the AAP paid claim did not have a significant 
effect on the rate of AAP paid claims during the study period.   
Off-Label Diagnostic Prescribing of Atypical Antipsychotic Medications 
Off-label diagnostic prescribing of atypical antipsychotics was common in 
pediatric patients in our study. During the study period, 62% (95% CI=62%, 63%) of 
paid claims for atypical antipsychotics in pediatric patients were classified as off-label 
diagnostic use. Much of the off-label diagnostic use was due to the lack of mental 
health diagnosis present in the medical visit (35%) associated with AAP paid claim.  
No diagnostic code for a mental health condition at the medical visit associated with 
the paid claim was classified as off-label diagnostic use. 
All covariates demonstrated significances as predictor in the univariate 
analysis (Table 4).   In the final multivariable model, age group (P value=0.05), 
gender (P value =0.002), mental health diagnosis (P value<0.001), provider category 
(P value=0.08), and US region (P value<0.001) were significant variables in the 
likelihood of off-label diagnostic prescribing of AAPs.  The adjusted odds ratios are 
presented in Table 4.  In the adjusted model, children 2-5 years old were 15% more 
likely (aOR)=1.15; 95% CI=1.0, 1.3) than children 13-17 years old to be prescribed 
atypical antipsychotics for off-label diagnostic indications.  Children aged 6-12 years 
old were 2% less likely to have off-label diagnostic (aOR=0.98; 95% CI=0.93, 1.0) 
use compared to adolescents (ages 13-17 years).  Female pediatric patients were 10% 
times more likely (aOR=1.1; 95% CI=1.0, 1.2) to be prescribed an AAP in an off-label 
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diagnostic manner compared to male children.  In the adjusted model, children located 
in the Midwest were 13% less likely (aOR=0.87; 95% CI=0.8, 0.97) to have an off-
label diagnostic AAP paid claim, compared to children located in the Northeast.  
Similarly, children located in the South US were 16% less likely (aOR=0.84; 95% 
CI=0.76, 0.92) to have off-label diagnostic AAP use, compared to children located in 
the Northeast.  The type of provider that a child received their AAP prescription from 
was not a significant predictor of off-label use by diagnosis in the adjusted model, 
when compared to prescriptions written by a specialty provider. After adjusting for 
other covariates, patients with a documented Mood or Anxiety Disorder were 95% less 
likely to receive an AAP medication for an off-label diagnosis (aOR=0.05; 95% 
CI=0.048, 0.053) compared to patient with psychotic, other or no mental health 
diagnosis present.  Also, patients with a documented DAB or developmental disorder 
were 97% less likely to receive an AAP medication for an off-label diagnosis 
(aOR=0.03; 95% CI=0.03, 0.04) compared to patients with psychotic, other or no 
mental health diagnosis present after adjusting for other covariates. 
2.5 Discussion 
The proportion of children receiving AAP medication therapy in a large private 
payer was small (<1%) but still meaningful.   Previous studies that included all 
children available for AAP prescribing, not only ones with documented mental health 
disorders, found similar rates of AAP medication therapy (<1% for children ages 2 to 
17).11  This low percentage is still meaningful, because it represents thousands 
(N=51,699) of children over the six year study period that are exposed to medications 
that have documented metabolic and cardiac long-term effects in adult patients.21,22  
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This study included all pediatric patients available in the study dataset during the study 
period for the denominator, because all of these patients were at risk for receiving 
AAP therapy for any reason, off-label or on-label.   
The exposure of these medications during childhood and the long-term effects 
on growth and metabolic measures are not clearly understood.  Over the last six years, 
trends in atypical antipsychotic prescribing demonstrated an overall increase in use 
among the privately-insured pediatric population.  The primary increase in AAP use 
occurred from 2010 to 2011.  In 2010, 6,923 (0.19%) children received a paid claim 
for an AAP medication.  Then in 2011, 8970 (0.25%) children received a paid claim 
for an AAP medication.  For the remainder of the study years, the prevalence was 
stable as illustrated in Table 1.  There was a slight increase in prevalence at the end of 
the study period, (2015), where 8,745 (0.28%) pediatric patients received AAP 
medication therapy.  During the study period in our sample, AAP medication 
utilization peaked in 2011.  This could be due to the increased availability of AAP 
medications on the US pharmaceutical market (Figure 1). Overall, by the end of the 
study period in 2015, pediatric patients had a 270% increase in AAP paid claim rate 
(RR=2.7; 95% CI=2.6, 2.9) compared to the start of the study period in 2010.   
Several patient characteristics demonstrated an association with the rate of 
AAP paid claims per year over the study period.  Gender had a significant association 
with the annual rate of paid claims over the study period, with female patients 
experiencing lower rates (RR=0.90; 95% CI=0.89, 0.92) of paid claims.  Children ages 
2-5 years (RR=1.2; 95% CI=1.1, 1.2) and 6-12 years (RR=1.2; 95% CI=1.1, 1.2) had 
an increase in the annual rate of paid claims over the study period, compared to older 
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children (ages 13-17).  This may indicate that over the last six years provider began 
utilizing AAP medications in a young patient population as familiarity with the 
medication class grows.  Geographic location of patient showed an association with 
the rate of AAP paid claims over the study period.  These minor differences could be 
due to local treatment practices and clinical preferences.    
Mental health diagnosis associated with the paid claim for an AAP 
demonstrated a significant association with the rate of AAP paid claims over the study 
period.  Patients with Developmental Disorders and Psychotic Disorders did not have 
a significantly different rate of paid claims for AAP medications over the study period, 
when compared to patients with no mental health diagnosis. This is finding is 
surprising, because previous trend studies have shown that use of atypical 
antipsychotics for Developmental Disorders was increasing overall and represented 
the highest rate of utilization compared to other mental health disorders.  Our study 
population had a much lower percentage of patients with Developmental Disorder 
(4%) compared to previous literature (53%).4  All clinical categories of mental health 
diagnoses were compared to the absence of mental health diagnosis in the medical 
visit around the paid claim.  In our study, 35% of paid claims did not have an 
associated mental health diagnosis.  Providers may withhold the documentation of 
mental health diagnosis due to potential stigma that could follow a pediatric patient 
through to adulthood.11,23 Some antipsychotics could be utilized for treatment for other 
conditions (insomnia, agitation) that do not meet clinical criteria as a mental health 
disorder.11,24   Finally, provider specialty or category did not demonstrate an 
association with the rate of paid AAP claims over the study period.  Our study found 
 60 
 
that whether a patient is seen by a primary care provider or a mental health specialist, 
the rate of AAP prescribing is comparable.   
Off-label prescribing can describe the use of medication therapy for indications 
that are not officially approved by the Food and Drug Administration.  Off-label use 
also includes using medications for unapproved age groups and at unapproved dosing 
levels for certain populations.  This study defined off-label diagnostic use as 
prescribing of an AAP medication with no documented mental health disorder or an 
unapproved mental health disorder.  Future studies should explore dosing levels of 
AAP paid claims and differentiated age groups to examine all types of off-label 
prescribing. Off-label use of atypical antipsychotic agents in pediatric patients is 
heavily debated.17,25  Many AAP medications have limited or no official FDA 
indication in children due to lack of research evidence in pediatric patients.  Our study 
found that off-label diagnostic prescribing of AAP medications occurred in 62% (95% 
CI=62%, 63%) of all paid claims.  This means that providers and patients were using 
AAP medications for other mental health diagnoses that have not been formally 
studied and approved by the FDA.  Our study found that off-label prescribing of 
atypical antipsychotics is common in the pediatric population. 
2.6 Limitations 
Our study assumed that a paid claim for an AAP represents therapy adhered to 
by the patient.  This assumes that the patient is exposed to a given medication because 
the paid claim was processed and therefore the patient adhered to the regimen.  This 
could overestimate the actual exposure to AAP medication therapy because patients 
may have been prescribed the AAP medication, but never actually consume the 
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prescription.  For the purposes of this study, only prescribing trends were evaluated, 
and outcomes based on patient exposure were not examined.    Future research that 
explores outcomes related to exposure of AAP could perform patient surveys or pill 
count methods to confirm the exposure to AAP medication therapy.   
A sizable percentage (35%) of paid claims for AAP medications was not 
associated with a mental health diagnosis of interest.  All patients included in the 
original cohort had a mental health diagnosis of interest to warrant inclusion in the 
cohort.  With so many patients missing a mental health diagnosis at associated medical 
visit, the rate of other categories of mental health disorder might be underrepresented.  
Many patients could have a diagnosis in one of the categories, but it is not documented 
and recorded in the “missing” category.  This can underestimate the true rate of the 
mental health diagnostic categories that are used for off-label analysis.  The lack of a 
mental health diagnosis associated with an AAP paid claim constituted off-label 
prescribing for the purposes of this study.  This could be overestimating the rate of 
off-label diagnostic use of AAP medications in this study because provider could have 
simply failed to properly document the reason for AAP use and this undocumented 
reason could align with an approved FDA indication.  Providers could justify this to 
protect a patient from the bias or stigma of mental health disease by not documenting a 
mental health diagnosis at medical visits. 
2.7 Conclusions 
Overall, the proportion of the pediatric population in a large privately-insured 
cohort receiving AAP medication therapy was small 0.28% (2015).  From 2010 to 
2015, atypical antipsychotic prescribing in privately-insured pediatric patients 
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increased from 0.19% in 2010 to 0.28% in 2015.  At the end of the study period, 
pediatric patients had a 270% increase in the rate of atypical antipsychotic prescribing 
per year compared to 2010.  Off-label prescribing represented 62% of atypical 
antipsychotic medication use and our study found it to be frequent practice in the 
pediatric population.  Several AAP agents (clozapine, ziprasidone and iloperidone) 
with no pediatric indication at all were still found to be used in the study population 
(6.7%).  Patients ages 2 to 5 years old were at an increased risk for using atypical 
antipsychotic medications for off-label diagnoses.  Female patients were at increased 
risk for using atypical antipsychotic medications for off-label diagnoses.  With these 
new insights, providers should consider more stringent use of atypical antipsychotic 
agents based on diagnosis until further safety studies are available specific to pediatric 
patients.   
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Table 1.  Atypical Antipsychotic Paid Claims for US Privately-Insured Children (2 to 17 years) 
from 2010 to 2015 (N=51,669 pediatric patients with 378,007 paid claims) 
  
Group 2010 2011 2012 2013 2014 2015 
Number of Eligible 
Pediatric patients in 
claims database 
3,562,685 3,525,172 3,474,515 3,404,207 3,308,273 3,182,170 
Number of AAP paid 
claims among 
children 
50,976 67,586 71,712 70,077 62,416 55,240 
Number of pediatric 
patients with at least 
one paid claim for an 
AAP medication 
6923 8970 9507 9091 8433 8745 
Percentage of 
Children receiving 
paid claim for AAP 
medication 
0.19% 0.25% 0.27% 0.27% 0.25% 0.28% 
 
 
 
Figure 1.  Percentage of Total Paid Claims (displayed by medication) for US Privately-Insured 
Children (2 to 17 years) for an Atypical Antipsychotic (2010 to 2015). 
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Table 2.  Baseline Patient and Clinical Characteristics of US Privately-Insured Children (2 to 17 
years) Receiving an Atypical Antipsychotic (AAP) Medication from 2010 to 2015 (N=40,750) 
 
Characteristic Pediatric Patients with an AAP Paid Claim 
(N=40,750) 
Age, y (mean, SD) 12.7 (3.7) 
Age Group, n (%)  
2-5 Years   2512 (6) 
6-12 Years 15913 (39) 
13-17 Years 22325 (55) 
Male, n (%) 23139 (57) 
US Region, n (%)  
   Northeast 4261 (11) 
   Midwest 11802 (29) 
   West 7332 (18) 
   South 17355 (43) 
Provider type, n (%)  
Acute Care Hospital 1910 (5) 
Mental Health Professional (non-physician) 4089 (10) 
Outpatient Facility 2368 (6) 
Primary Care Provider 8029 (20) 
Specialist 16077 (40) 
Therapy Provider (Social Worker, Psychologist) 2450 (6) 
Other Non-Physician Provider 5827 (14) 
Diagnosis associated with AAP prescription, n (%)  
Anxiety Disorders 4465 (11) 
Mood Disorders 11449 (28) 
Disruptive or Aggressive Behavior Disorders 5509 (14) 
Developmental Disorders 1495 (4) 
Psychotic Disorders 1407 (4) 
Other MH Disorders 2265 (6) 
No MH Diagnosis Present 14160 (35) 
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Table 3.  Rate Ratios (RRs) with 95% Confidence Intervals (CIs) Derived From an Adjusted GEE 
Model of Patient and Clinical Factors Associated with Prescribing of Atypical Antipsychotic 
Medication in US Privately-Insured Pediatric Patients (2 to 17 years) from 2010 to 2015.  
(N=40,750) 
Variable Rate Ratios (95% CI’s) p-value 
Time (Study Year)  <0.001 
2010  Reference 
2011 1.57 (1.5, 1.7)  
2012  1.63 (1.5, 1.7)  
2013 1.79 (1.7, 1.9)  
2014 1.74 (1.7, 1.8)  
2015 2.71 (2.6, 2.9)  
Gender  <0.001 
Male Reference 
Female 0.90 (0.89, 0.92) 
Age Group   <0.001 
2-5 Years 1.2 (1.1, 1.2) 
6-12 Years 1.2 (1.1, 1.2) 
13-17 Years Reference 
Region  0.13 
Northeast 1.04 (1.0, 1.1) 
Midwest 1.03 (1.0, 1.1) 
South 1.0 (0.98, 1.0) 
West Reference 
Mental Health Diagnosis  <0.001 
Anxiety Disorders 0.86 (0.83, 0.89) 
Mood Disorders 0.91 (0.89, 0.93) 
Disruptive or Aggressive Behavior 
Disorders 
0.94 (0.91, 0.97) 
Developmental Disorders 1.1 (0.99, 1.0) 
Psychotic Disorders 1.1 (1.0, 1.2) 
Other Mental Health Disorders 0.79 (0.75, 0.82) 
No Mental Health Diagnosis Present Reference 
Provider Category  0.35 
Acute Care Hospital 1.0 (0.97, 1.1) 
Mental Health Professional (non-physician) 1.0 (0.98, 1.1) 
Outpatient Facility 1.1 (1.0, 1.1) 
Primary Care Provider 1.0 (0.98, 1.1) 
Specialist 1.0 (0.99, 1.1) 
Therapy Provider (Social Worker, 
Psychologist) 
1.0 (0.95, 1.1) 
Other non-physician provider Reference 
*General estimating equations used with a Poisson variance and log-link.  Final model adjusted for the following 
baseline covariates: Age group, gender, US region and Mental Health Diagnosis. 
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Table 4.  Odds Ratios (ORs) with 95% Confidence Intervals (CIs) Derived from an Adjusted 
GEE Model of Patient and Clinical Factors Associated with Any Off-Label Diagnostic 
Prescribing of Atypical Antipsychotic Medication in US Privately-Insured Pediatric Patients (2 to 
17 years) from 2010 to 2015. (N=37,274 patients; 78,481 paid claims) 
Variable Odds Ratios (95% CIs) p-value 
  
Patient Age 1.0 (1.0, 1.1) 0.05 
Age Group (years)   0.05 
2-5 years 1.15 (1.0, 1.3) 
6-12 years 0.98 (0.93, 1.0) 
13-17 years (adolescents) Reference 
Gender  0.002 
Female 1.1 (1.0, 1.2) 
Male Reference 
Region  <0.001 
Midwest 0.8 (0.80, 0.97) 
South 0.84 (0.76, 0.92) 
West 0.99 (0.89, 1.1) 
Northeast Reference 
Mental Health Diagnosis**  <0.001 
Anxiety or Mood Disorders 0.05 (0.05, 0.06) 
DAB*** and Developmental 
Disorders 
0.03 (0.03, 0.04) 
Psychotic, Other or NO MH Diagnosis 
Present 
Reference 
Provider Category  0.08 
Acute Care Hospital 1.1 (0.98, 1.2) 
Mental Health Professional (non-
physician) 
1.0 (0.97, 1.1) 
Outpatient Facility 0.98 (0.91, 1.1) 
Primary Care Provider 1.0 (0.98, 1.1) 
Specialist Reference 
Therapy Provider (Social Worker, 
Psychologist) 
1.0 (1.0, 1.2) 
Other non-physician provider 1.1 (1.0, 1.1) 
 *General estimating equations used with a Binomial variance and log-link.  Final model adjusted for the following 
baseline covariates: Age group, gender, US region, Mental Health Diagnosis, and Provider category. 
**Mental Health Diagnosis categories combined as described in above table.  Patients receiving medication off-
label did not have any diagnosis of Disruptive/Aggressive Behavior Disorders or Psychotic Disorders noted.  
Patients receiving medications “on-label” did not have any diagnoses of Anxiety Disorders, Developmental 
Disorders, Other Disorders or Missing. 
***Disruptive and Aggressive behavior (DAB) 
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3.1 Abstract 
OBJECTIVE:  This analysis aims to determine the risk of readmission for mental 
health treatment for pediatric patients treated with oral atypical antipsychotics (AAPs) 
upon discharge from initial mental health inpatient admission.  Examine patient and 
clinical characteristics that are associated with risk of readmission with oral atypical 
antipsychotic treatment.   
METHODS:  Inpatient hospitalization and pharmacy claims from the OPTUMInsight 
administrative dataset (Optum Clinformatics ® Data Mart; OptumInsight, Eden 
Prairie, MN) from 2010 to 2015 were analyzed.  Children ages 2 to 17 years old with 
an inpatient admission for a mental health diagnosis of interest and discharged on an 
oral AAP were included in the study sample (N =3,028).  A Cox proportional hazards 
regression model was used to evaluate if exposure to different oral AAPs agents, 
including risperidone, aripiprazole, quetiapine, etc., was associated with a delay in the 
time until readmission for mental health stabilization.   Other patient and clinical 
characteristics and their association with delayed time until readmission was analyzed.   
RESULTS:  For all children with an index admission for mental health treatment, the 
mean age of the study cohort was 14.8 years (standard deviation (SD) = 2.3).  Of all 
3,084 patients, 85% of patients were aged 13-17 years old or in adolescence.  The 
cohort had slightly more male patients than female patients, (59% vs. 46%, P 
value<0.001).  In pediatric patients admitted for mental health treatment, 73% of 
patients had a Mood Disorder as their primary mental health diagnosis (P value= 
0.02).   In the study cohort, aripiprazole was the more frequently utilized discharge 
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AAP (42%).  Overall, the Charlson Comorbidity Index (CCI) score for the entire 
cohort was not significantly different between the groups and most patients (92%) 
included in this cohort had a CCI score of zero.  In the analysis examined by discharge 
AAP, patients receiving risperidone were younger (13.6, SD=2.8, P value <0.001) 
compared to other discharge AAPs.  More male patients received risperidone as a 
discharge AAP, (70%, p<0.001) compared to other AAP agents.  Children with a 
primary mental health diagnosis of Mood Disorders received aripiprazole, quetiapine 
or ziprasidone more often for discharge therapy (80%, 76%, 75%, respectively; P 
value <0.001) than other AAP agents.  In the unadjusted model, quetiapine (hazard 
ratio (HR)=0.69, 95% confidence interval (95% CI)=0.47, 1.0) and ziprasidone 
(HR=0.52, 95% CI=0.28, 0.97) prescribed for a patient upon discharge form index 
admission demonstrated a significant lower risk of readmission, compared to 
risperidone. 
In the adjusted Cox proportional hazards model, female gender was associated with a 
significantly higher risk (adjusted hazard ratio (aHR) =1.5, 95% CI=1.2, 1.8), of 
readmission for mental health treatment.  Patients with no prior treatment with AAP 
medication before index admission were 8.9 times more likely (aHR=8.9, 95% 
CI=3.7, 21.8) to be readmitted for mental health treatment.   In the adjusted model, 
patients receiving quetiapine (aHR=0.55, CI=0.37, 0.81) and ziprasidone (aHR=0.55, 
CI=0.29, 1.0) upon discharge had a lower risk of readmission, compared to 
risperidone.   In the weighted cumulative incidence curves, 13% of patients receiving 
risperidone, 12.5% of patients who were taking aripiprazole and 10 % of patient 
receiving olanzapine were readmitted within the follow-up period.  In comparison, 7% 
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of patient receiving quetiapine and 5.5% of patients receiving ziprasidone were 
readmitted within the follow-up period.  
CONCLUSIONS:  Patients receiving quetiapine and ziprasidone had a lower risk of 
readmission, compared to risperidone when used at discharge in pediatric patients.  
The cumulative incidence of readmission was lower in patients receiving quetiapine 
and ziprasidone upon discharge. Pediatric patients of a female gender had a 
significantly higher risk of readmission.  Patients with no recent prior exposure to 
AAP mediation therapy in the 3-month prior to index admission were at a much higher 
risk of readmission for mental health treatment.  Future studies should examine the 
adverse events of these agents in the pediatric population.  This additional safety data 
can determine if these agents should be considered for increased use in clinical 
practice for in pediatric patients to reduce the risk of readmission for mental health 
treatment.    
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3.2 Introduction 
Several randomized, controlled trials have demonstrated that atypical 
antipsychotic medications, such as risperidone, olanzapine, aripiprazole and 
quetiapine, produce fewer adverse effects and offer better psychotic symptom relief in 
a short course than other agents in pediatric patients with mental health disorders.1–6  
However, there is limited information available about the comparative effectiveness of 
these medications in clinical practice settings, specifically in pediatric patients.7  A 
major indication of drug effectiveness in clinical practice is relapse.  In regards to 
mental health disorders, this relapse is characterized by worsening symptoms or 
changes in behavior that become harmful to the patient and/or society.8  Time to 
readmission for inpatient mental health treatment is a commonly used measure for 
assessing relapse and effectiveness of mental health therapies.8,9  Available follow-up 
studies in adults indicate that up to 50% of patients with schizophrenia and other 
psychotic disorders are readmitted within one year post discharge.10,11  This high rate 
of readmission is particularly concerning because a higher rate of relapse is associated 
with worse long-term prognosis in adult mental health patients.11  .  Poor adherence to 
antipsychotic therapy has been shown to increase risk of relapse and hospitalization 
with a related increase in related healthcare resource utilization and costs.12–15  Patients 
often try several antipsychotic agents over the course of treatment due to side effects 
or varying efficacy in the individual patient.  No studies are yet available comparing 
the rates of readmission with atypical antipsychotics in pediatric patients 
According to 2008 research using data from the Healthcare Cost and 
Utilization Project (HCUP), there were 356,000 hospital admissions for psychotic 
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disorders in the US, representing 19% of all mental health hospitalizations.16   These 
patients had an average length of stay of 11.1 days and average cost per admission was 
$7,500.16,17   Patients who experienced a recent relapse (within previous 6 months) 
were found to have four times higher costs compared to patients without a recent 
mental health relapse.17  This study focused primarily on adult patients and only 
included patients diagnosed with schizophrenia12,13,16,17  A 2014 report analyzing 
admissions for mental health treatment in pediatric patients estimated the cost of 
hospital visits (inpatient and emergency department) to be $11.6 million from 2006 to 
2011, based on HCUP data.18    In 2014, 10% of all hospitalizations in children over 
the age of 3 years were for a primary mental health diagnosis.19  Previous research 
followed adult schizophrenic patients for two years and found statistically significant 
differences between atypical antipsychotic agents in regards to risk of increased 
readmission rates.9,20  To the best of our knowledge, no study has yet examined a 
direct comparison of oral atypical antipsychotic agents in privately-insured pediatric 
patients with mental health conditions to delay hospital readmission for mental health 
treatment. 
This study focused on pediatric patients who utilized oral atypical 
antipsychotic therapy after an initial admission for mental health treatment.  
Readmission for mental health treatment was evaluated to determine the efficacy of 
using specific atypical antipsychotics in pediatric mental health patients.  Many 
randomized controlled trials and post-marketing trials demonstrated the efficacy of 
individual oral agents in the reduction in readmission in adults patients, compared to 
placebo or first generation antipsychotics.21–23   Furthermore, clinical providers often 
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extrapolate the demonstrated benefit of these agents in adults to pediatric patients with 
limited direct evaluation among children.24  This study evaluated the effectiveness of 
specific oral AAP agents in delaying readmission in pediatric patients. 
3.3 Methods 
Study Design 
The study was a retrospective cohort study utilizing the administrative dataset 
(Optum Clinformatics ® Data Mart; OptumInsight, Eden Prairie, MN) from January 1, 
2010 to December 31, 2015.  This data set contains medical, including inpatient and 
outpatient, and relevant information about hospital admissions.  This data included 
commercial health insurance claims (inpatient and outpatient medical records, 
laboratory data, facility information, and outpatient pharmacy) and enrollment data 
from large, private insurer across the United States.25  This dataset provides healthcare 
information on 36 million beneficiaries and encompasses 1.2 billion individual 
medical records.  Pediatric patients represent about 10% of this dataset or 3.5 million 
children.  The inpatient admission file provided clinical information on date of 
admission, diagnosis codes for admission, length of stay (LOS) and discharge date. 
The inpatient file contains up to five diagnoses associated with an admission or 
encounter available for evaluation.  Pharmacy claims data included medication 
information such as days’ supply, quantity, prescribing physician and cost data.  This 
dataset represents approximately 36 million covered patients across the United States.  
The index date was the date of the first hospital admission for a mental health 
diagnosis during the study period.  A look-back period of 90 days from index 
admission date was examined to ensure no prior admission for mental health treatment 
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was present.    Patients were followed for up to one year from the discharge date of the 
index hospitalization.  According to studies evaluating inpatient mental health 
treatment in adults, the highest risk of readmission is in the first-year post-discharge, 
so this same follow-up period was chosen. 
Inclusion Criteria 
The study included all patients with an inpatient admission for a mental health 
diagnosis aged 2-17 years.  Admission for a mental health diagnosis was determined 
by utilizing International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) and International Classification of Diseases, Tenth 
Revision, Clinical Modification (ICD-10-CM) diagnostic codes listed in Appendix A.  
Eligible patients required at least 90 days or continuous health plan enrollment before 
index admission and 365 days after the index admission.9, 24  Patients were included 
only if they received an atypical antipsychotic medication (AAP) upon discharge from 
index admission.  Patients were identified as having an AAP medication paid claim 
using National Drug Codes (NDCs) as provided in Appendix B, for an available AAP 
medication on the US market.  All available dosage forms and atypical antipsychotic 
medications were included in the analysis.  Patients were determined to have received 
an AAP medication upon discharge if a paid claim was present for an AAP within 14 
days post discharge date.  
Exclusion Criteria  
Patients will be excluded from the study if they were older than 17 years at 
index hospitalization and no paid claim within 14 days for atypical antipsychotic 
medication therapy.9, 24  The 14-day post discharge date window was used to identify a 
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paid claim as representing a discharge prescription from the index admission.  This 
window was defined based on clinical practice parameters from the American 
Academy of Child and Adolescent Psychiatry that recommend follow-up 
appointments post hospitalization occur within 7-14 days to provide continuity of care 
across levels of mental health treatment.26  Patients who were hospitalized for mental 
health treatment during the study period in the recent months preceding the index 
admission were excluded.  A look back period of 90-days was examined for any recent 
admissions for mental health treatment.  Patients were included in study cohort if their 
index admission was for a mental health diagnosis.  A 90-day look back period from 
index admission was performed to examine prior exposure to AAP therapy and 
patients were classified as having no prior exposure, exposure to same AAP as 
discharge agent or exposure to different AAP as discharge medication.  Figure 1 
describes the study cohort with relevant exclusion or inclusion criteria.     
Exposures and Outcomes 
The exposure of interest was the use of atypical antipsychotic therapy at time 
of hospital discharge.20  Exposure to specific AAP agents was evaluated and each 
agent was compared to risperidone.  Risperidone was chosen as the reference agent 
because it was the first atypical antipsychotic to be awarded an Food and Drug 
Administration (FDA) indication for use in pediatric patients.  The primary outcome 
evaluated was time from index hospital discharge to readmission for any mental-health 
related diagnosis (Appendix A). 
Covariates considered sufficient to adjust for confounding included the 
following at baseline: age, gender, admission diagnosis, length of hospital stay, 
Charlson Comorbidity Index (CCI) and AAP exposure (same AAP as discharge, 
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different AAP as discharge or no AAP therapy) prior to index hospitalization.  
Admission diagnosis was categorized in to groups listed in Appendix A and compared 
to diagnosis codes in the “other” category.  The other category was used as the 
reference group because it contains mental health diagnoses that AAP agents do not 
have a FDA approved indication and should have the lowest exposure risk to AAPs 
since no official FDA indication is present.  The CCI score was used to evaluate the 
severity of illness among patients at their index hosptialization.27   The CCI score 
measures the severity of the presence of certain disease states, such as malignancies, 
HIV, and diabetes, in the patient’s inpatient medical file at index admission and 
represents the overall health status of the patient.  Appendix C provides a full listing 
of the disease states included in the CCI score and point values associated with each 
diagnosis.  Length of stay (LOS) of index admission was examined as a covariate and 
represented in number of days as a continuous variable.  Patients were followed to 
ascertain hospital readmission with a related MH diagnosis and were censored at the 
date of death (as recorded in a hospital claim), one-year post discharge of the index 
admission or end of the study period (31 December 2015), whichever occurred first.   
Statistical Analysis  
We reported descriptive statistics to characterize each outcome group of 
interest (readmission for mental health treatment or no readmission). Baseline 
characteristics were also examined by discharge AAP (exposure group) and presented 
in Table 2.  Group comparisons on baseline sample characteristics were performed 
using chi-square tests or Fisher-exact tests for categorical variables and Analysis of 
Variance (ANOVA)  for continuous variables.   Baseline characteristics of patients at 
 79 
 
index discharge were examined and included covariates age, gender and United States 
region.  We used a Cox proportional hazards regression model to assess hazard (i.e., 
risk) of psychiatric readmission post-discharge within one year of index admission. 
Baseline covariates for adjustment in the models included age group, gender, index 
admission diagnosis, CCI score, region, pre-index AAP exposure and discharge AAP 
agent.28,29  The Schoenfeld residuals were examined to determine if the proportional 
hazard assumption was violated.29  All covariates except for age showed no evidence 
of a violation of proportional hazards through this statistical test [(LOS, P 
value=0.36), (Gender, P Value=0.84), (Region, P Value=0.26), (CCI Score, P 
Value=0.98), (MH Diagnosis, P Value=0.12), (Prior AAP exposure, P Value=0.37) 
and (Discharge AAP, P Value=0.14)]. The proportional hazard assumption for the 
covariate age group was not satisfied (P value = 0.02); therefore, the model was 
stratified by age group to allow for separate baseline hazards for each age group.30  All 
pairwise interactions between covariates were not statistically significant in a single 
contrast (P value=0.56).  These values indicated that none of the interactions of 
covariates were significant, so interaction terms were not included in the final model.  
Collinearity between independent variables was tested using Variance Inflation 
Factors (VIF) test and no significant collinearity was found; thus, no adjustments for 
collinearity were made in the final model.  Covariates associated with the outcome 
with P value less than 0.20 in the univariate analysis were included in the final 
adjusted model.28  Gender (P value<0.001), prior AAP mediation exposure  (P value 
<0.001), mental health diagnosis (P value=0.11) and discharge AAP medication (P 
value=0.14) demonstrated a significant effect on risk of readmission during the study 
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period and all of these covariates were included in the adjusted model. CCI score was  
non-significant and was not included in the adjusted analysis.  The length of stay 
(LOS) was not found to have a significant effect on risk of increased readmission and 
LOS was not included in the adjusted model.  We used Efron’s method to handle tied 
event times.29,31   Cumulative incidence curves were generated using inverse 
probability weights to adjust for the baseline covariates.  All statistical tests were two-
sided and performed at the 0.05 significance level. Analyses were performed using 
SAS Enterprise Guide Version 7.1 (Cary, North Carolina, USA). 
3.4 Results 
During the study period 2010 to 2015, 3,215 pediatric patients were admitted 
with a mental health diagnosis documented as the reason for admission. After applying 
inclusion criteria of receiving an AAP medication upon discharge (within 14-day 
window), 3,084 patients had a qualifying index admission for mental health treatment 
during the study period.  Of those subjects, 313 (10%) children had a readmission 
within one year of the index admission discharge date for a mental health diagnosis or 
readmission for mental health treatment.  The study sample is presented in Figure 1.   
Study Cohort disposition and characteristics 
For the entire cohort, the mean age of the study cohort was 14.8 years 
(standard deviation (SD) = 2.3).  Of all patients evaluated, 85% of patients were ages 
13-17 years old or adolescents.  The cohort had slightly more male patients than 
female patients, (53% vs. 47%).  In pediatric patients admitted for mental health 
treatment, 73% of patients had a Mood Disorder as their primary mental health 
diagnosis (72.5%).  In the study cohort, aripiprazole was the more frequently utilized 
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discharge AAP (41.8%).  Overall the CCI score for the entire cohort was not 
significantly different between the groups (patients readmitted vs. patients not 
readmitted) and most patients (92%) included in this cohort had a CCI score of zero 
(Table 1).  This was expected since the components of the CCI score are primarily 
chronic illnesses and these conditions are usually present in higher frequencies as a 
population ages. 
Baseline characteristics of readmission versus no readmission patients are 
displayed in Table 1.  Children readmitted for mental health treatment during the 
follow up period were slightly higher in age (15.2 years. vs. 14.7 yrs., P value=0.006).  
The group that was readmitted for mental health treatment has a significantly larger 
proportion of female patients (59% vs 46%, P value<0.001).  The percentage of 
children with no prior AAP exposure in the three months preceding index admission 
was higher in readmitted group compared to the children not readmitted within the 
follow-up period (91.7% vs. 59.7%, P value<0.001).  The admission mental health 
diagnosis differed significantly between the children readmitted for treatment, and 
those that were not (P value=0.007).  Children readmitted for mental health treatment 
had a higher proportion of documented diagnoses for Mood Disorders (77% vs. 72%) 
than children not readmitted.  Children readmitted for mental health treatment had a 
lower proportion of documented diagnoses for Disruptive or Aggressive Behavior 
Disorders (5% vs. 9%).  The mean length of index hospital admission did not 
significantly vary between the two groups (8.2 days vs. 8.0 days, P value =0.85).  The 
region of residence did not vary significantly between the two groups (P value=0.60).    
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The CCI score was zero in 92% of patients in both groups and was not significantly 
different (P Value =0.86).   
Baseline characteristics of children in the cohort analyzed by exposure 
(discharge atypical antipsychotic agent) are presented in Table 2.  Patients receiving 
risperidone were younger (13.6, SD=2.8, P value<0.001) compared to other discharge 
AAPs.  More male patients received risperidone as a discharge AAP, (70%, P 
value<0.001) compared to other AAP agents (47%).  Children receiving risperidone 
upon discharge had documented disruptive or aggressive behavior disorders as 
primary diagnosis  more often than children receiving other AAP agents upon 
discharge (13% vs. 7%, respectively; P value<0.001).  Children with a primary mental 
health diagnosis of Mood Disorders received quetiapine, aripiprazole or ziprasidone 
more often for discharge therapy (80%, 76% and 75%, respectively; P value <0.001) 
compared to other AAP agents.  CCI score did not vary significantly between 
discharge AAP exposure groups at baseline. 
Table 3 summarizes the results of the unadjusted and adjusted models. In the 
unadjusted model, several baseline patient characteristics displayed a significant 
association with the hazard of readmission for mental health treatment. Female 
patients had a 60% increased risk of readmission (hazard ratio, (HR) =1.6; 95% 
confidence interval, (CI) =1.2, 2.5) compared to male patients.  Patients with a 
primary diagnosis of disruptive or aggressive behaviors disorders (DAB) had a 55% 
decreased risk of readmission (HR=0.45; 95% CI=0.23, 0.89) compared to children 
with a diagnosis of other mental health disorders.  Similarly, patients with a primary 
diagnosis of Developmental Disorders had a 65% decreased risk of readmission 
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(HR=0.35; 95% CI=0.12, 0.98) compared to children diagnosed with other mental 
health disorders.  Children with no prior AAP exposure in the three months prior to 
index admission were 10 times more likely to be readmitted for mental health 
treatment (HR=10.2; 95% CI=4.2, 24.7).  Patients receiving quetiapine had a 31% 
decreased risk of readmission (HR=0.69; 95% CI=0.47, 1.0) compared to patients 
receiving risperidone.  In the unadjusted model, patients receiving ziprasidone had a 
48% decreased risk of readmission (HR = 0.52; 95% CI = 0.28, 0.97) compared to 
patients receiving risperidone.  Finally, patients receiving “other” AAP agents 
(lurasidone, asenapine, clozapine, iloperidone and paliperidone) had a 71% decrease 
risk of readmission for mental health treatment (HR=0.29; 95% CI=0.11, 0.79) 
compared to risperidone. CCI score was zero in 92% in patients at baseline and was 
not included  in Cox proportional hazard model. LOS (P value =0.70) and geographic 
region (P value=0.93) were not significantly associated with time to readmission.   
In the adjusted Cox proportional hazards analysis, female patients had 50% 
increased risk of readmission for mental health treatment (adjusted hazard ratio 
(aHR)=1.5; 95% CI =1.2, 1.8).  Patients with no prior treatment with AAP medication 
before index admission had 8.9 times the risk (aHR=8.9; 95% CI=3.7, 21.8) of 
readmission for mental health treatment. In the final adjusted model, choice of atypical 
antipsychotic agent for discharge therapy demonstrated a significant effect on the risk 
of readmission. Patients receiving quetiapine at discharge had a 45% decreased risk 
(aHR=0.55; 95% CI=0.37, 0.81) and patients receiving ziprasidone had a 45% 
decreased risk (aHR=0.55; 95% CI=0.29, 1.0) of being readmitted for mental health 
treatment, compared to patients receiving risperidone.  In the adjusted model, primary 
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mental health diagnosis was no longer significantly associated with the hazard of 
being readmitted for mental health treatment during the follow-up period (P value = 
0.14). 
The unadjusted cumulative incidence of readmission is presented in Figure 2 
and the inverse probability weighted cumulative incidence curves are presented in 
Figure 3, examined by discharge AAP agents.  In the unadjusted curves, 14% of 
patients receiving aripiprazole, 12% of patients taking risperidone, and 9% of patients 
receiving olanzapine were readmitted by one-year after discharge.  In comparison, the 
unadjusted model shows that 8% of patients receiving quetiapine and 6% of patients 
receiving ziprasidone were readmitted within the follow-up period.  After using 
inverse probability weighting, the adjusted curves show that 13% of patients receiving 
risperidone, 12.5% of patients who were taking aripiprazole and 10% of patients 
receiving olanzapine were readmitted by one-year after discharge.  In comparison, 7% 
of patients receiving quetiapine and 5.5% of patients receiving ziprasidone were 
readmitted during the follow-up period.   
3.5 Discussion 
In the adjusted model, patients exposed to quetiapine and ziprasidone 
demonstrated a lower risk (aHR=0.55; 95% CI=0.37, 0.81; aHR=0.55; 95% CI=0.29, 
1.0, respectively) of readmission, compared to risperidone.  As represented in Figure 
3, choice of discharge atypical antipsychotic does have a significant association with 
the risk of being readmitted for mental health treatment within the follow-up period in 
pediatric patients after adjusting for baseline covariates.  Pediatric patients receiving 
quetiapine or ziprasidone also displayed a lower cumulative incidence of readmission 
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(Figure 3) over study period compared to patients receiving risperidone at discharge, 
after adjusting for baseline covariates    Risperidone is one of the most frequently 
prescribed in the pediatric population for mental health treatment.  This analysis 
suggests that patients might be at a lower risk of relapse when treated with quetiapine 
and ziprasidone and alternative AAP therapy may be more effective than risperidone.  
A longer follow-up period is needed to compare effectiveness of atypical 
antipsychotics.8    In addition, discharge from the hospital does not imply adherence to 
the discharge medication therapy in the outpatient setting and this study did not 
consider adherence.  Risperidone might be poorly tolerated in this patient population 
due to problematic side effects or poor therapeutic response. This could cause patients 
to discontinue discharge therapy prior to the completion of the prescription. If patients 
are no longer on risperidone discharge therapy, then the effect of this intervention on 
readmission risk can be unclear.  Future studies should examine discharge therapy 
continuation to evaluate the role medication adherence in efficacy of discharge 
AAPs.32 
Female patients demonstrated a higher risk of one-year readmission for mental 
health treatment compared to male patients.  This differs from adult studies, that 
indicated that gender was not a significant predictor of readmission.32,33  Patients who 
were recently naïve to AAP medication therapy or received no treatment for the three 
months prior to hospitalization were at a significantly higher risk of readmission at 
one-year that patients receiving therapy prior to index admission (aHR=8.9; 95% 
CI=3.7, 218).  Often several therapies must be explored and tailored based on patient 
response and side effects before a maintenance therapy can be established.  Patients 
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who had no recent exposure to AAP medication therapy could experience more 
adverse medication reactions or incomplete therapeutic response, which can require 
them to be readmitted for stabilization. 
 Our study focused on pediatric patients and many of the disease states 
evaluated using the CCI are chronic in nature and more prevalent as age progresses, so 
a majority of this pediatric study population (92%) demonstrated a CCI score of zero.  
This was expected since the components of the CCI score are primarily chronic 
illnesses and these conditions are usually present in higher frequencies as a population 
ages.  Most of the disease states analyzed in the CCI are chronic in nature (diabetes 
complications, congestive heart failure, etc.) and do not occur frequently in children.   
No specific comorbidity index is available and sufficiently validated for use in 
pediatric patients, though there is forthcoming work for a pediatric-specific index.34  
Disease states that are more prevalent in children, such as asthma, childhood leukemia 
or autism, might be present in this cohort. However, the CCI index does not identify 
these diagnoses and they are not factored into the overall score that is intended to 
represent health status.  Therefore, some underlying confounding by indication might 
be present if the patients that experience a readmission are sicker at baseline, but the 
disease severity is not fully captured by the CCI score.  This study did not expressly 
evaluate cost of admission or treatment, but length of hospitalization was included as a 
covariate.  Overall length of hospitalization can represent higher costs for the 
admission and poorer long-term clinical outcomes for mental health treatment, so 
overall length of stay (LOS) was examined as a covariate.20 Overall length of 
hospitalization can represent higher costs for the admission and poorer long-term 
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clinical outcomes for mental health treatment, so overall length of stay (LOS) was 
examined as a covariate and was defined as a continuous variable for number of days 
of admission.20  
Based on the weighted cumulative incidence curves, the “other” category of 
atypical antipsychotic agents trended toward a lower risk of readmission for mental 
health treatment, when compared to risperidone.  This class represents lurasidone, 
asenapine, paliperidone, iloperidone and clozapine, all newer agents to the US market 
or agents with no pediatric indication for use.  Evidence for the efficacy of these 
agents is limited in this study due to the low utilization of AAPs in this category.  
Further studies with higher utilization of these newer agents are needed to better 
understand this trend. 
The model was stratified by gender and full results are presented in Appendix 
D.  The adjusted model for the entire cohort indicated possible unmeasured 
confounding was present and some of underlying differences may be correlated with a 
patient’s gender.  After stratifying the model by gender, it was found that male 
patients had a higher rate of risperidone use as a discharge AAP (32%) compared to 
female patients (15%).  Of note, male patients also had a higher rate of documented 
disruptive and aggressive behavior (DAB) (12%) disorders than compared to female 
patients (4%).  Other demographics were similar between both groups in the study 
cohort.  Previous research in pediatric patients found AAP agents were use more often 
in patients with documented DAB disorders (37.8%) compared to other mental health 
diagnoses.1  Risperidone is one of the only AAP agents with a specific pediatric 
indication for use in DAB disorders.  Both factors could explain the differences in 
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AAP selection and mental health diagnosis in the male portion of the study cohort.    
Overall, the findings of readmission risk were similar for all other covariates in the 
models separated by gender, except for discharge AAP.  In the complete, adjusted 
model, the risk of readmission for patients given zisprasidone was 45% lower 
compared to risperidone (aHR=0.55, 95% CI=0.29, 1.0).  Also, patients given 
quetiapine had a 45% lower risk of readmission compared to risperidone (aHR=0.55, 
95% CI=0.37, 0.81).  Once stratified by gender, female patients given zisprasidone 
had a 37% lower risk and male patients given zisprasidone had a 65% lower risk 
(aHR=0.63, 95% CI=0.30, 1.3; aHR=0.35, 95% CI=0.08, 1.4) , respectively).  This 
decreased risk with zisprasidone compared to risperidone no longer reached the level 
of significant.  When stratified by gender, female patients given quetiapine had a 48% 
lower risk of readmission and male patients given quetiapine had a 36% lower risk of 
readmission (aHR=0.52, 95% CI=0.31, 0.88; aHR=0.64, 95% CI=0.4, 1.0, 
respectively).  This association remained significant, even when stratified by gender.  
The association between discharge AAP agent and risk of readmission was somewhat 
attenuated within each gender. 
3.6 Limitations 
This study only evaluated AAP medication therapy received upon discharge 
from a mental health hospital admission.  The permanence of this therapy or switches 
in treatment was not evaluated.  This study only evaluated the exposure to an agent at 
the time of discharge and other therapies within the follow up time were not evaluated.  
This could lead to exposure misclassification.  Therapy switching and therapy 
permanence (PDC) between discharge and readmission should be analyzed to 
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determine if certain oral AAP therapies are more effective.  This study examined the 
difference in one-year hazard of readmission after prescribed an atypical antipsychotic 
agent at discharge.  The “other” category trended toward a lower risk of readmission, 
but the use of these newer agents was low, and the determination of efficacy warrants 
further study.   Once these new agents are utilized in clinical practice, future studies 
can evaluate evidence in administrative claims databases and determine if these agents 
are effective at lowering the risk of readmission. Some unmeasured confounding 
might be present for variables that we were unable to capture or did not examine in 
this study.  Combination therapy with multiple AAPs or compliance with counseling 
or behavioral therapy has been documented to improve clinical outcomes and prevent 
relapse.15,17  This study focused on analyzing the impact of discharge medication 
therapy with AAPs on risk of readmission, so switching therapy or combination 
therapy was not evaluated at this time.  Mental health treatment often includes 
counseling services and other behavioral therapy interventions.  This study analyzed 
the impact of medication therapy interventions on readmission outcomes specifically 
and did not explore the impact of other treatment modalities.  Mental health treatment 
is often multifaceted and patient success is dependent on many treatment modalities.  
Therapy services and group counseling provide support to the patient and play a vital 
role, along with medications, to treatment success.  These treatment options and 
combinations of therapy with medications were not examined in this study but should 
be included in future research for their impact on mental health treatment success. 
3.7 Conclusions 
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 Patients receiving quetiapine and ziprasidone had a lower risk of readmission, 
compared to risperidone when used at discharge in pediatric patients.  Newer atypical 
antipsychotic agents trended toward demonstrating a lower risk of readmission and 
future studies are warranted to see if these agents have a significant effect on 
readmission in pediatric patients.  The cumulative incidence of readmission was lower 
in patients receiving quetiapine and ziprasidone upon discharge, compared to 
risperidone.  Quetiapine and ziprasidone might want to be considered for increased use 
in clinical practice for in pediatric patients to reduce the risk of readmission for mental 
health treatment.   Pediatric female patients had a significantly higher risk of 
readmission for mental health treatment.  Patients with no prior exposure to AAP 
mediation therapy in the 3-month prior to index admission were at a much higher risk 
of readmission for mental health treatment.  Further studies are warranted to evaluate 
factors, such as adverse events and therapy compliance, that might further mediate this 
increased risk.   
 91 
 
3.8 References 
1.  Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A Randomized, 
Double-Blind, Placebo-Controlled Study of Risperidone Maintenance Treatment 
in Children and Adolescents with Disruptive Behavior Disorders. 
2006;163(3):402-410. 
2.  Van Bellinghen M, de Troch C. Risperidone in the Treatment of Behavioral 
Disturbances in Children and Adolescents with Borderline Intellectual 
Functioning: A Double-Blind, Placebo-Controlled Pilot Trial. J Child Adolscent 
Psychopharmacol. 2004;11(1):5-13. 
3.  Hollander E, Wasserman S, Swanson E, et al. A Double-Blind Placebo-
Controlled Pilot Study of Olanzapine in Childhood/Adolescent Pervasive 
Developmental Disorder. J Child Adolscent Psychopharmacol. 2006;16(5):541-
548. 
4.  Findling R, Robb A, Nyilas M, et al. A Multiple-Center, Randomized, Double-
Blind, Placebo-Controlled Study of Oral Aripiprazole for Treatment of 
Adolescents with Schizophrenia. J Child Adolscent Psychopharmacol. 
2008;165(11):1432-1441. 
5.  Marcus R, Owen R, Kamen L, et al. A Placebo-Controlled, Fixed-Dose Study of 
Aripiprazole in Children and Adolescents with Irritability Associated with 
Autistic Disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-1119. 
6.  Correll C. Antipsychotic use in children and adolescents: minimizing adverse 
effects to maximize outcomes. J Am Acadmeny Child Adolesc Psychiatry. 
2008;47:9-20. 
7.  Ghanizadeh A, Sahraeizadeh A, Berk M. A Head-to-Head Comparison of 
Aripiprazole and Risperidone for Safety and Treating Autistic Disorders, a 
Randomized Double Blind Clinical Trial. Child Psychiatry Hum Dev. 
2014;45(2):185-192. 
8.  Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. 
Rehospitalization Rates of Chronically Ill Schizophrenic Patients Discharged on 
a Regimen of Risperidone, Olanzapine, or Conventional Antipsychotics. Am J 
Psychiatry. 2001;158(2):266-269. 
9.  Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic 
Adherence and rehospitalization in Schizophrenia Patients Receiving Oral 
Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. J 
Manag Care Spec Pharm. 2015;21(9):754-768. 
10.  Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term 
outcome in schizophrenia. J Clin Psychiatry. 1996;57:53-60. 
 92 
 
11.  Sheitman B, Lee H, Strauss R, Lieberman J. The evaluation and treatment of 
first-episode psychosis. Schizophr Bull. 1997;23:653-661. 
12.  dosReis S, Johnson E, Steinwachs D. Antipsychotic Treatment Patterns and 
Hospitalizations Among Adults with Schizophrenia. Schizophr Res. 2008;101(1-
3):304-311. 
13.  Ahn J, McCombs J, Jung C. Classifying Patients by Antipsychotic Adherence 
Patterns Using Latent Class Analysis: Characteristics of nonadherent Groups in 
the California Medicaid (Medi-Cal) program. Value Health. 2008;11(1):48-56. 
14.  O’Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A. Long-Term Cost-
Effectiveness of Atypical Antipsychotics in the Treatment of Adults with 
Schizophrenia in the US. Clin Outcomes Res. 2013;5:459-470. 
15.  Ascher-Svanum  h, Zhu B, Faries D, Furiak N, Montgomery W. Medication 
Adherence Levels and Differential Use of Mental-Health Services in the 
Treamtent of Schizophrenia. BMC Res Notes. 2009;2(6). 
16.  Agency for Healthcare Research and Quality. HCUP Facts and Figures: 
Statistics on Hospital-Based Care in US, 2008. Rockville, MD: Agency for 
Healthcare Research and Quality; 2010. 
17.  Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in 
Schizophrenia: Costs, clinical Outcomes and Quality of Life. Br J Psychiatry. 
2004;184:346-361. 
18.  Torio CM, Encinosa W, Berdahl T, McCormick MC, Simpson LA. Annual 
Report on Health Care for Children and Youth in the United States: National 
Estimates of Cost, Utilization and Expenditures for Children with Mental Health 
Conditions. Acad Pediatr. 2015;15(1):19-35. 
19.  Bardach N, Coker T, Zima B, et al. Common and Costly Hospitalizations for 
Pediatric Mental Health Disorders. Pediatrics. 2014;133(4):602-609. 
20.  Kim E, You M, Pikalov A, Van-Tran Q, Jing Y. One-Year Risk of Psychiatric 
Hospitalization and Associated Treatment Costs in Bipolar Disorder Treated with 
Atypical Antipsychotics: A Retrospective Claims Database Analysis. BMC 
Psychiatry. 2011;11(6):1-9. 
21.  Geddes J, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of 
schizophrenia: systematic overview and meta-regression analysis. BMJ. 
2000;321:1371. 
22.  Maher AR, Maglione M, Bagley S. Efficacy and Comparative Effectiveness of 
Atypical Antipsychotic Medications for Off-Label Uses in Adults A Systematic 
Review and Meta-analysis. JAMA. 2011;306(12):1359-1369. 
 93 
 
23.  Stroup T, Lieberman J, McEvoy J, et al. Effectiveness of Olanzapine, Quetiapine, 
Risperidone, and Ziprasidone in Patients with Chronic Schizophrenia Following 
Discontinuation of a Previous Atypical Antipsychotic. J Lifelong Learn 
Psychiatry. 2006;4(4):539-552. 
24.  Alexander G, Gallagher S, Mascola A, Moloney R, Stafford R. Increasing off-
label use of antipsychotic medications in the United States, 1995–2008. 
Pharmacoepidemiol Drug Saf. 2011;20(2):177-184. 
25.  OPTUM. OPTUM (R) Clinformatics DataMart: DataSheet. 2016. 
https://www.optum.com/content/dam/optum/resources/productSheets/Clinformat
ics_for_Data_Mart.pdf. Accessed March 26, 2017. 
26.  McClellan J, Stock S, American Academy of Child and Adolescent  Psychiatry 
(AACAP) Committee on Quality Issues. Practice Parameter for the Assessment 
and Treatment of Children and Adolescents with Schizophrenia. J Am Acadmeny 
Child Adolesc Psychiatry. 2013;52(9):976-990. 
27.  Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali. New ICD-
10 version of the Charlson Comorbidity Index predicted in-hospital mortality. J 
Clin Epidemiology. 2004;57:1288-1294. 
28.  Collett D. Modelling Survival Data in Medical Research. 2nd Edition. Boca 
Raton: Chapman & Hall/CRC; 2003. 
29.  Kleinbaum DG, Klein M. Survival Analysis: A Self Learning Text. 3rd Edition. 
Spring Science & Business Media; 2012. 
30.  Cole S, Hernan M. Adjusted survival curves with inverse probability weights. 
Comput Methods Programs Biomed. 2003;75:45-49. 
31.  Efron B. The Efficiency of Cox’s Likelihood Function for Censored Data. J Am 
Stat Assoc. 1976;72(59):557-565. 
32.  Patel N, Dorson PG, Edwards N, Mendelson S, Crismon M. One-Year  
Rehospitalization rates of patients discharged on atypical versus conventional 
antipsychotics. Psychiatr Serv. 2002;53(7):891-893. 
33.  Lin C-H, Lin S-C, Chen M-C, Wang S-Y. Comparison of Time to 
Rehospitalization Among Schizophrenic Patients Discharged on Typical 
Antipsychotics, Clozapine or Risperidone. J Chin Med Assoc. 2006;69(6):264-
269. 
34.  Tai D, Dick P, To T. Development of Pediatric Comorbidity Prediction Model. 
Arch Pediatr Adolesc Med. 2006;160(3):293-299. 
 
 94 
 
 
Figure 1.  Selection of US Pediatric Privately-Insured Patients (2 to 17 years) for Analyses of Oral 
Atypical Antipsychotic Agents and Risk of Readmission for Mental Health Treatment (2010 to 
2015) 
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Table 1.  Demographic and Clinical Characteristics of Privately-Insured, US Children (2 to 17 
years) with an Index Inpatient Admission for Mental Health Treatment from 2010 to 2015 by 
Readmission Status (N=3,084) 
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine 
 
Characteristic Children with 
readmission (N=313) 
Children with no 
readmission (N=2,771) 
p-value 
 
Patient Age, Years, Mean+ SD 15.2 (15.0, 15.5) 14.7 (14.6,14.8) 0.002 
Length of Stay (LOS, days) 8.2 (7.3, 9.1) 8.0 (7.5, 8.6) 0.85 
Follow Time, (days), Median (Q1, Q3) 95.3 (84, 107) 308 (304, 312) <0.001 
Age Group (years) N (%)* 0.0032 
2-12 years  30 (9.6) 441 (15.9)  
13-17 years (adolescents) 283 (90.4) 2330 (84.1)  
Patient Gender, N (%) <0.001 
Male 128 (40.9) 1489 (53.7)  
Female 185 (59.1) 1282 (46.3)  
Patient Region, N (%) 0.60 
Northeast 36 (11.5) 264 (9.5)  
Midwest 87 (27.8) 810 (29.2)  
South 135 (43.1) 1247 (45.0)  
West 55 (17.6) 450 (16.2)  
MH Diagnosis Category, N (%) 0.002 
Anxiety Disorder 21 (6.7) 145 (5.2)  
Mood Disorders 240 (76.7) 1996 (72.0)  
Disruptive or Aggressive Behavior 
Disorders 
15 (4.8) 238 (8.6)  
Developmental Disorders 4 (1.3) 119 (43)  
Psychotic Disorders 3 (1.0) 78 (2.8)  
Other MH Disorders 30 (9.6) 195 (7.0)  
Prior AAP exposure   <0.001 
No prior AAP exposure at index 
admission 
287 (91.7) 1653 (59.7)  
Treatment with same AAP as discharge 
(index admission) 
21 (6.7) 779 (28.1)  
Treatment with different AAP as 
discharge (index admission) 
5 (1.6) 339 (12.2)  
Discharge Atypical Antipsychotic Agent 0.011 
Risperidone (Risperdal) 82 (26.2) 653 (23.6)  
Quetiapine (Seroquel) 41 (13.1) 482 (17.4)  
Aripiprazole (Abilify) 157 (50.2) 1138 (41.1)  
Ziprasidone (Geodon) 11 (3.5) 175 (6.3)  
Olanzapine (Zyprexa) 18 (5.8) 205 (7.4)  
Other* 4 (1.3) 117 (4.2)  
Charlson Comorbidity Score (on Index admission) 0.86 
0 289 (92.3) 2567 (92.6)  
1 24 (7.7) 202 (7.3)  
2 0 (0) 2 (0.08)  
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Table 2.  Baseline Demographic and Clinical Characteristics of Privately Insured, US Children (2 
to 17 years) with Index Inpatient Admission for Mental Health Treatment from 2010 to 2015, 
Analyzed by Discharge Atypical Antipsychotic. (N=3,084) 
 
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine 
Variable Risperidone 
(N=735) 
Quetiapine 
(N=523) 
Aripiprazole 
(N=1295) 
Ziprasidone 
(N=186) 
Olanzapine 
(N=223) 
Other* 
(N=121) 
p-value 
Patient Age, Years, 
Mean (SD) 
13.6 (2.8) 15.2 (2.1) 14.7 (2.3) 14.6 (2.2) 14.3 (2.5) 14.6 (2.2) <0.001 
Length of Stay 
(LOS, days),  
7.5 (7.6) 7.9 (6.0) 7.9 (18.7) 8.5(8.0) 8.6 (6.1) 12.9 (29.0) 0.006 
Follow time, Days, 
Mean (SD) 
286 (126) 298 (118) 280 (125) 298 (117) 287 (126) 293 (118) 0.05 
Age Group (years) n (%)  <0.001 
2-12  204 (27.8) 46 (8.8) 159 (12.3) 21 (11.3) 31 (13.9) 10 (8.3)  
13-17  531 (72.2) 477 (91.2) 1136(87.7 165 (88.7) 192 (86.1) 111 (91.7)  
Patient Gender n (%) <0.001 
Male 514 (69.9) 226 (43.2) 618 (47.7) 82 (44.1) 124 (55.6) 53 (43.8)  
Female 221 (30.1) 297 (56.8) 677 (52.3) 104 (55.9) 99 (44.4) 68 (56.2)  
Patient Region, n (%) <0.001 
Northeast 83 (11.3) 45 (8.6) 141 (10.9) 14 (7.5) 8 (3.6) 9 (7.4)  
Midwest 246 (33.5) 162 (31.0) 341 (26.3) 56 (30.1) 54 (24.2) 37 (30.6)  
South 311 (42.3) 209 (40.0) 624 (48.2) 91 (48.9) 84 (37.7) 63 (52.1)  
West 95 (12.9) 107 (20.5) 189 (14.6) 25 (13.4) 77 (34.5) 12 (9.9)  
MH Diagnosis Category, n (%) <0.001 
Anxiety Disorder 55 (7.5) 23 (4.4) 61 (4.7) 3 (1.6) 17 (7.6) 7 (5.8)  
Mood Disorder 461 (62.7) 416 (79.5) 985 (76.1) 140 (75.3) 145 (65.0) 88 (72.7)  
DAB Disorders 101 (13.7) 20 (3.8) 91 (7.0) 16 (8.6) 17 (7.6) 8 (6.6)  
Developmental 
Disorders 
44 (6.0) 6 (1.2) 38 (2.9) 12 (6.5) 18 (8.1) 5 (4.1)  
Psychotic Disorders 26 (3.5) 9 (1.7) 25 (1.9) 7 (3.8) 8 (3.6) 6 (5.0)  
Other MH Disorders 48 (6.5) 49 (9.4) 95 (7.3) 8 (4.3) 18 (8.1) 7 (5.8)  
Prior AAP Exposure, n (%) <0.001 
No prior AAP 
exposure 
473 (64.4) 354 (67.7) 839 (64.8) 92 (49.5) 132 (59.2) 49 (40.5)  
Treatment with 
same AAP as 
discharge (index 
admission) 
187 (25.4) 104 (19.9) 385 (29.7) 55 (29.6) 34 (15.3) 35 (28.9)  
Treatment with 
different AAP as 
discharge (index 
admission) 
75 (10.2) 65 (12.4) 71 (5.5) 39 (21.0) 57 (25.6) 37 (30.6)  
Charlson Comorbidity Score (On Index Admission), n (%) 0.41 
0 685 (93.2) 485 (92.7) 1189 (91.8) 171 (91.9) 212 (95.1) 113 (93.4)  
1 50 (6.8) 38 (7.3) 105 (8.1) 15 (8.1) 10 (4.5) 8 (6.6)  
2 0 (0) 0 (0) 1 (0.1) 0 (0) 1 (0.4) 0 (0)  
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Table 3.  Unadjusted and Adjusted Hazard Ratios of Readmission derived from a Cox 
Proportional Hazards Model for Privately-Insured US Children (2 to 17 years) with an Index 
Admission for Mental Health Treatment, in database 2010 to 2015 (N=3,084) 
 
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine 
Variable Hazard Ratio 
 (95 CIs) 
P-value Hazard Ratios 
(Adjusted) 
p-value 
 
Index Admission, Length of Stay 
(LOS) 
1.0 (0.99, 1.02) 0.88   
Age Group   0.007  
Violated the proportional 
hazards assumption.  Model 
stratified on age, so no hazard 
ratio generated 
 
2-12 years 1.7 (1.2, 2.5) 
13-17 years Reference 
Patient Gender <0.001                               0.002 
Female 1.6 (1.3, 2.1) 1.5 (1.2, 1.8) 
Male Reference Reference 
Patient Region 0.84   
Northeast 1.1 (0.71, 1.7)   
Midwest 0.86 (0.6, 1.2)   
West 0.83 (0.6, 1.2)   
South Reference   
MH Diagnosis Category 0.35                            0.14 
Anxiety Disorder 1.3 (0.77, 2.3) 1.1 (0.60, 1.9) 
Mood Disorders 1.0 (0.71, 1.5) 0.83 (0.57, 1.2) 
Disruptive or Aggressive Behavior 
Disorders 
0.45 (0.23, 0.89) 0.58 (0.31, 1.1) 
 
Developmental Disorders 0.35 (0.12, 0.98) 0.37 (0.12, 1.1) 
Psychotic Disorders 0.50 (0.18, 1.4) 0.36 (0.11, 1.2) 
Other MH Disorders Reference Reference 
Prior AAP exposure <0.001                              <0.001 
No prior AAP exposure 10.2 (4.2, 24.7) 8.9 (3.7, 21.8) 
Treatment with same AAP as 
discharge (index admission) 
1.8(0.66, 4.7) 1.6 (0.6, 4.2) 
Treatment with different AAP as 
discharge (index admission) 
Reference Reference 
Discharge Atypical Antipsychotic 
Agent 
0.14                              0.006 
Risperidone (Risperdal) Reference Reference 
Quetiapine (Seroquel) 0.69 (0.47, 1.0) 0.55 (0.37, 0.81) 
Aripiprazole (Abilify) 1.1 (0.84, 1.4) 0.93 (0.71, 1.2) 
Ziprasidone (Geodon) 0.52 (0.28, 0.97) 0.55 (0.29, 1.0) 
Olanzapine (Zyprexa) 0.72 (0.43, 1.2) 0.73 (0.43, 1.2) 
Other* 0.29 (0.11, 0.79) 0.35 (0.13, 0.97) 
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Figure 2.  Unadjusted Cumulative Probability of Readmission from 2010 to 2015 for Mental 
Health Treatment by AAP Medication at Discharge, in US Privately-Insured Children (2 to 17 
years) from 2010 to 2015 (N=313) 
 
 
 
 
Figure 3.  Weighted Cumulative Probability of Readmission from 2010 to 2015 for Mental Health 
Treatment by Atypical Antipsychotic Medication at Discharge, in Privately-Insured US Children 
(2 to 17 years) from 2010 to 2015 (N=313) 
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APPENDIX A 
MENTAL HEALTH DIAGNOSES OF INTEREST FOR STUDY 
POPULATION 
International Classification of Disease 9th Edition [ICD-9] medical codes (2012)  
International Classification of Disease 10th Edition [ICD-10] medical codes (2017) 
(Halloran, Swindle, Takemoto, & Schnitzler, 2010; Olfson, King, & Schoenbaum, 2015; Patel, 
Crismon, & Shafer, 2006) 
 
 
Diagnosis ICD-9-CM ICD-10-CM 
Anxiety Disorders 300-300.3, 300.5-300.9, 309.2x, 309.4, 
309.81, 313.0 
F40-F48 
Mood Disorders 296, 300.4, 301.1x, 309.0, 309.1, 311, 313.1 F30-F39 
Disruptive/aggressive 
Behavior disorders 
309.3, 312.xx, 313.81, 314.xx, V40.3, V40.9 F90-F98 
Developmental 
Disorders 
299.0, 315-319, V40.0-V40.2, V79.2 F70-F79, F80-F89 
Psychotic Disorders 292.1x, 293-295.9, 297-298.9, 299, 299.1-
299.91, 368.16, 780.1 
F20-F29 
Miscellaneous/Other 
Disorders 
290-292.0, 292.2-292.2, 301-301.0, 301.2-
307.59, 307.8-309, 309.8, 309.82-310.9, 313, 
313.2-313.8, 313.82-313.9, 660-331.9, V66.3, 
V67.3, V71.0 
F99, F50-F59, F60-
F69 
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APPENDIX B 
ATPYICAL ANTIPSYCHOTIC AGENTS AVAILABLE ON US MARKET  
(“Drugs@FDA: FDA Approved Drug Products,” 2017) 
 
Medication FDA pediatric indication Year of Indication 
Approval 
Risperidone Schizophrenia (13-17 yrs.) 
Bipolar I (10-17 yrs.) 
Irritability with Autistic Disorder (5-16 yrs.) 
2007 
2007 
2007 
Olanzapine Schizophrenia (13-17 yrs.) 
Bipolar I (13-17 yrs.) 
2010 
2009 
Aripiprazole Schizophrenia (13-17 yrs.) 
Bipolar I (10-17 yrs.) 
Irritability with Autistic Disorder (6-17 yrs.) 
2007 
2008 
2009 
Paliperidone Schizophrenia (12-17 yrs.) 2011 
Quetiapine Schizophrenia (13-17 yrs.) 
Bipolar I (10-17 yrs.) 
2009 
2009 
Ziprasidone None none 
Lurasidone Schizophrenia (13-17 yrs.) 2017 
Clozapine None None 
Iloperidone None None 
Asenapine Bipolar I (10-18 yrs.) 2015 
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APPENDIX C 
 
CHARLSON COMORBIDITY INDEX, DIAGNOSTIC CATEGORIES  
(Sundararajan et al., 2004) 
 
 
Condition Weights ICD-9-CM Codes ICD-10-CM Codes 
Acute myocardial 
infarction 
1 410, 412 121, 122, 125.2 
 
Congestive Heart 
Failure 
1 428 109.9, 111, 113, 113.2, 125.5, 142, 
142.5-142.9, 143, 150, P29 
Peripheral vascular 
Disease 
1 441, 4439, 7854, V4334 170, 171, 173, 173.8, 173.9, 177.1, 
179-179.2, K55.1, K55.8, K55.9, 
295.8, 295.9 
Cerebral vascular 
accident 
1 430-438 G45, G46, H34, 160-169 
Dementia 1 290 F00-F03, F05, G30, G31 
Pulmonary disease 1 490, 491, 492, 493, 494, 
495, 496, 500, 501, 502, 
503, 504, 505 
127.8, 127.9, 140-147, 160-167, 
J68.4, J70.1, J70.3 
Connective tissue 
disorder 
1 7100, 7101, 7104, 7140, 
7141, 7142, 71481 (now 
5171), 725 
M05, M06, M31.5, M32-M34, 
M35.1, M35.3, M36.0 
Peptic ulcer 1 531, 532, 533, 534 K25-K28 
Liver disease 1 5712, 5714, 5715, 5716 B18, K70.0-K70.3, K70.9, K71.3-
K71.5, K71.7, K73, K74, K76.0, 
K76.2-K76.4, K76.8, K76.9, Z94.4 
Diabetes 1 2500, 2501, 2502, 2503, 
2507 
E10.0, E10.l, E10.6, E10.8, E10.9, 
E11.0, E11.1, E11.6, E11.8, E11.9, 
E12.0, E12.1, E12.6, E12.8, E12.9, 
E13.0, E13.1, E13.6, E13.8, E13.9, 
E14.0, E14.1, E14.6, E14.8, E14.9 
Diabetes 
complications 
2 2504, 2505, 2506 E10.2-E10.5, E10.7, E11.2-E11.5, 
E11.7, E12.2-E12.5, E12.7, E13.2-
E13.5, E13.7, E14.2-E14.5, E14.7 
Paraplegia 2 342, 3441 G04.1, G11.4, G80.1, G80.2, G81, 
G82, G83.0-G83.4, G83.9 
Renal disease 2 285, 2830, 5831, 5832, 
5833, 5835, 5836, 5837, 
5834, 5855, 86588 
I12.0, I13.1, N03.2-N03.7, N05.2-
N05.7, N18, N19, N25.0, Z49.0-
Z49.2, Z94.0, Z99.2 
Cancer 2 14, 15, 16, 18, 170, 171, 
172, 174, 175, 176,179, 
190, 192, 193, 194, 1950, 
1951, 1952, 1953, 1954, 
1955, 1958, 200, 201, 202, 
203, 204, 205, 206, 
207,208 
C00-C26, C30-C34, C37-C41, C43, 
C45-C58, C60-C76, C81-C85, C88, 
C90-C97 
Metastatic cancer 3 196, 197, 198, 1990, 1991 C77-C80 
Severe liver disease 3 5722, 5723, 5724, 5728 I85.0, I85.9, I86.4, I98.2, K70.4, 
K71.1, K72.1, K72.9, K76.5, 
K76.6, K76.7 
HIV 6 042, 043, 044 B20-B22, B24 
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APPENDIX D 
STUDY 3 RESULTS: STRATIFIED BY GENDER 
Demographic and Clinical Characteristics of Privately-Insured, Male, US Children (2 to 17 years) 
with an Index Inpatient Admission for Mental Health Treatment from 2010 to 2015 by 
Readmission Status (N=1,617) 
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine 
Characteristic Children with 
readmission 
(N=128) 
Children with no 
readmission 
(N=1,489) 
p-value 
 
Patient Age, Years, Mean+ SD 14.8 (14.3, 15.2) 14.3 (14.2, 14.5) 0.06 
Length of Stay (LOS, days) 7.3 (6.2, 8.4) 8.4 (7.4, 9.4) 0.54 
Follow Time, (days), Median (Q1, Q3) 97.2 (78.4, 116) 309 (304, 314) <0.001 
Age Group (years) N (%)* 0.11 
2-12 years  21 (16.4) 335 (22.5)  
13-17 years (adolescents) 107 (83.6) 1154 (77.5)  
Patient Region, N (%) 0.12 
Northeast 20 (115.6) 137 (9.2)  
Midwest 39 (30.5) 458 (30.8)  
South 50 (39.1) 645 (43.3)  
West 19 (14.8) 249 (16.7)  
MH Diagnosis Category, N (%) 0.13 
Anxiety Disorder 10 (7.8) 66 (4.4)  
Mood Disorders 92 (71.9) 979 (65.8)  
Disruptive or Aggressive Behavior 
Disorders 
12 (9.4) 186 (12.5)  
Developmental Disorders 3 (2.3) 95 (6.4)  
Psychotic Disorders 3 (2.3) 58 (3.9)  
Other MH Disorders 8 (6.3) 105 (92.9)  
Prior AAP exposure   <0.001 
No prior AAP exposure at index 
admission 
116 (90.6) 841 (56.5)  
Treatment with same AAP as discharge 
(index admission) 
10 (7.8) 456 (30.6)  
Treatment with different AAP as 
discharge (index admission) 
2 (1.6) 192 (12.9)  
Discharge Atypical Antipsychotic Agent 0.05 
Risperidone (Risperdal) 50 (39.1) 464 (31.2)  
Quetiapine (Seroquel) 15 (11.7) 211 (14.2)  
Aripiprazole (Abilify) 54 (42.2) 564 (37.9)  
Ziprasidone (Geodon) 2 (1.6) 80 (5.4)  
Olanzapine (Zyprexa) 6 (4.7) 118 (7.9)  
Other* 1 (0.8) 52 (3.5)  
Charlson Comorbidity Score (on Index admission) 0.91 
0 118 (92.2) 1375 (92.3)  
1 10 (7.8) 112 (7.5)  
2 0 (0) 2 (0.13)  
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Baseline Demographic and Clinical Characteristics of Privately Insured, Male, US Children (2 to  
17 years) with Index Inpatient Admission for Mental Health Treatment from 2010 to 2015,  
Analyzed by Discharge Atypical Antipsychotic. (N=1,617) 
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine  
Variable Risperidone 
(N=514) 
Quetiapine 
(N=226) 
Aripiprazole 
(N=618) 
Ziprasidone 
(N=82) 
Olanzapine 
(N=124) 
Other* 
(N=53) 
p-value 
Patient Age, 
Years, Mean 
(SD) 
13.9 (2.7) 15.3 (1.9) 15.0 (2.1) 15.1 (1.9) 14.7 (2.2) 15.3 (1.8) <0.001 
Length of Stay 
(LOS, days),  
7.5 (7.6) 8.5 (10) 7.2 (6.9) 7.8 (6.4) 8.6 (6.1) 11.1 (19.8) 0.008 
Follow time, 
Days, Mean 
(SD) 
289 (124) 299 (117) 292 (119) 289 (123) 298 (115) 291 (114) 0.92 
Age Group (years) n (%)  <0.001 
2-12  164 (32.0) 27 (12.0) 117 (29.0) 15 (18.3) 23 (18.6) 10 (18.9)  
13-17  350 (68.0) 199 (88.0) 501 (81.0) 67 (81.7) 101 (81.5) 43 (81.1)  
Patient Region, N (%) <0.001 
Northeast 56 (10.9) 20 (8.9) 67 (10.8) 5 (6.1) 5 (4.0) 4 (7.6)  
Midwest 177 (34.4) 70 (31.0) 173 (28.0) 23 (28.1) 33 (26.6) 21 (39.6)  
South 215 (41.8) 84 (37.2) 291 (47.1) 41 (50.0) 40 (32.3) 24 (45.3)  
West 66 (12.8) 52 (23.0) 87 (14.1) 13 (15.9) 46 (37.1) 4 (7.6)  
MH Diagnosis Category, n (%) <0.001 
Anxiety 
Disorder 
32 (6.2) 5 (2.2) 31 (5.0) 1 (1.2) 4 (3.2) 3 (5.7)  
Mood 
Disorder 
301 (58.6) 175 (77.4) 425 (68.8) 56 (68.3) 80 (64.5) 34 (64.2)  
DAB 
Disorders 
87 (16.9) 12 (5.3) 70 (11.3) 9 (11.0) 14 (11.3) 6 (11.3)  
Developmental 
Disorders 
33 (6.4) 5 (2.2) 35 (5.7) 9 (11.0) 11 (8.9) 5 (9.4)  
Psychotic 
Disorders 
23 (4.5) 4 (1.8) 21 (3.4) 3 (3.7) 7 (5.7) 3 (5.7)  
Other MH 
Disorders 
38 (7.4) 25 (11.1) 36 (5.8) 4 (4.9) 8 (6.5) 2 (3.8)  
Prior AAP Exposure, n (%)  <0.001 
No prior AAP 
exposure 
322 (62.7) 144 (63.7) 364 (58.9) 33 (40.2) 75 (60.5) 19 (35.9)  
Treatment with 
same AAP as 
discharge 
(index 
admission) 
135 (26.3) 53 (23.5) 214 (34.6) 29 (35.4) 20 (16.1) 15 (28.3)  
Treatment with 
different AAP 
as discharge 
(index 
admission) 
57 (11.1) 29 (12.8) 40 (6.5) 20 (24.4) 29 (23.4) 19 (35.9)  
Charlson Comorbidity Score (On Index Admission), n (%) 0.39 
0 483 (94.0) 209 (92.5) 563 (91.1) 75 (91.5) 116 (93.6) 47 (88.7)  
1 31 (6.0) 17 (7.5) 54 (8.7) 7 (8.5) 7 (5.7) 6 (11.3)  
2 0 (0) 0 (0) 1 (0.2) 0 (0) 1 (0.8) 0 (0)  
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Unadjusted and Adjusted Hazard Ratios of Readmission based on a Cox Proportional Hazards 
Model for Privately-Insured, Male, US Children (2 to 17 years) with an index admission for 
Mental Health Treatment, in database 2010 to 2015 (N=1,617) 
 
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine 
Variable Hazard Ratio 
 (95 CIs) 
P-value Hazard Ratios 
(Adjusted) 
p-value 
 
Index Admission, Length of Stay 
(LOS) 
1.0 (0.98, 1.0) 0.51   
Age Group   0.13  
Violated the proportional 
hazards assumption.  Model 
stratified on age, so no 
hazard ratio generated 
 
2-12 years 1.4 (0.90, 2.3) 
13-17 years Reference 
Patient Region 0.08  0.02 
Northeast Reference Reference  
Midwest 0.61 (0.36, 1.0) 0.55 (0.32, 0.95)  
West 0.56 (0.33, 0.93) 0.44 (0.26, 0.74)  
South 0.56 (0.30, 1.0) 0.45 (0.23, 0.85)  
MH Diagnosis Category 0.13 0.27 
Anxiety Disorder 2.0 (0.78, 5.0) 1.1 (0.60, 1.9) 
Mood Disorders 1.2 (0.58, 2.5) 0.83 (0.57, 1.2) 
Disruptive or Aggressive Behavior 
Disorders 
0.84 (0.34, 2.0) 0.58 (0.31, 1.1) 
 
Developmental Disorders 0.41 (0.11, 1.5) 0.37 (0.12, 1.1) 
Psychotic Disorders 0.64 (0.17, 2.4) 0.36 (0.11, 1.2) 
Other MH Disorders Reference Reference 
Prior AAP exposure <0.001 <0.001 
No prior AAP exposure 12.2 (3.0, 49.4) 10.3 (2.5, 42.0) 
Treatment with same AAP as 
discharge (index admission) 
2.1 (0.46, 9.6) 1.8 (0.4, 8.2) 
Treatment with different AAP as 
discharge (index admission) 
Reference Reference 
Discharge Atypical Antipsychotic 
Agent 
0.09 0.26 
Risperidone (Risperdal) Reference Reference 
Quetiapine (Seroquel) 0.67 (0.37, 1.2) 0.64 (0.4, 1.0) 
Aripiprazole (Abilify) 0.89 (0.60, 1.3) 0.90 (0.61, 1.3) 
Ziprasidone (Geodon) 0.25 (0.06, 1.0) 0.35 (0.08, 1.4) 
Olanzapine (Zyprexa) 0.48 (0.21, 1.1) 0.53 (0.22, 1.2) 
Other* 0.19 (0.03, 1.4) 0.29 (0.04, 2.1) 
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Demographic and Clinical Characteristics of Privately-Insured, Female, US Children (2 to 17 
years) with an Index Inpatient Admission for Mental Health Treatment from 2010 to 2015 by  
Readmission Status (N=1,467) 
 
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine 
 
Characteristic Children with 
readmission 
(N=185) 
Children with no 
readmission 
(N=1,282) 
p-value 
 
Patient Age, Years, Mean+ SD 15.5 (1.8) 15.2 (1.9) 0.11 
Length of Stay (LOS, days) 8.8 (8.9) 7.7 (6.6) 0.04 
Follow Time, (days), Median (Q1, Q3) 93.9 (97.5) 307 (107) <0.001 
Age Group (years), n (%)* 0.11 
2-12 years  9 (4.9) 106 (8.3)  
13-17 years (adolescents) 176 (95.1) 1176 (91.7)  
Patient Region, n (%) 0.60 
Northeast 16 (8.7) 127 (9.9)  
Midwest 48 (26.0) 352 (27.5)  
South 85 (46.0) 602 (47.0)  
West 36 (19.5) 201 (15.7)  
MH Diagnosis Category, n (%) 0.033 
Anxiety Disorder 11 (6.0) 79 (6.2)  
Mood Disorders 148 (80) 1017 (79.3)  
Disruptive or Aggressive Behavior 
Disorders 
3 (1.6) 52 (4.1)  
Developmental Disorders 1 (0.5) 24 (1.9)  
Psychotic Disorders 0 (0) 20 (1.6)  
Other MH Disorders 22 (11.9) 90 (7.0)  
Prior AAP exposure, n (%)   <0.001 
No prior AAP exposure at index 
admission 
171 (92.4) 812 (63.3)  
Treatment with same AAP as discharge 
(index admission) 
11 (6.0) 323 (25.2)  
Treatment with different AAP as 
discharge (index admission) 
3 (1.6) 147 (11.5)  
Discharge Atypical Antipsychotic Agent, n (%) 0.01 
Risperidone (Risperdal) 32 (17.3) 189 (14.8)  
Quetiapine (Seroquel) 26 (14.1) 271 (21.2)  
Aripiprazole (Abilify) 103 (55.7) 574 (44.8)  
Ziprasidone (Geodon) 9 (4.9) 95 (7.4)  
Olanzapine (Zyprexa) 12 (6.5) 87 (6.8)  
Other* 3 (1.6) 65 (5.1)  
Charlson Comorbidity Score (on Index admission), n (%) 0.79 
0 171 (92.4) 1192 (93.0)  
1 14 (7.6) 90 (7.0)  
2 0 0  
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Baseline Demographic and Clinical Characteristics of Privately Insured, Female, US  
Children (2 to 17 years) with Index Inpatient Admission for Mental Health Treatment from 2010  
to 2015, Analyzed by Discharge Atypical Antipsychotic. (N=1,467) 
 
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine 
Variable Risperidone 
(N=221) 
Quetiapine 
(N=297) 
Aripiprazole 
(N=677) 
Ziprasidone 
(N=104) 
Olanzapine 
(N=99) 
Other* 
(N=68) 
p-value 
Patient Age, 
Years, Mean 
(SD) 
14.6 (2.5) 15.4 (1.7) 15..4 (1.7) 15.5 (1.7) 15.2 (1.9) 15.7 (1.2) <0.001 
Length of Stay 
(LOS, days),  
7.6 (7.3) 8.0 (5.7) 7.4 (7.2) 9.0 (8.2) 8.3 (6.4) 9.0 (7.1) 0.16 
Follow time, 
Days, Mean 
(SD) 
278 (128) 298 (119) 268 (130) 306 (112) 274 (137) 294 (122) 0.003 
Age Group (years) n (%)  <0.001 
2-12  40 (18.1) 19 (6.4) 42 (6.2) 6 (5.8) 8 (8.1) 0 (0.0)  
13-17  181 (81.9) 278 (93.6) 635 (93.8) 98 (94.2) 91 (91.9) 68 (100)  
Patient Region, N (%) <0.001 
Northeast 27 (12.2) 25 (8.4) 74 (10.9) 9 (8.7) 3 (3.0) 5 (7.4)  
Midwest 69 (31.2) 92 (31.0) 168 (24.8) 33 (31.7) 21 (21.2) 16 (23.5)  
South 96 (43.4) 125 (42.1) 333 (49.2) 50 (48.1) 44 (44.4) 39 (57.4)  
West 29 (13.1) 55 (18.5) 102 (15.1) 12 (11.5) 31 (31.3) 8 (11.8)  
MH Diagnosis Category, n (%) <0.001 
Anxiety 
Disorder 
23 (10.4) 18 (6.1) 30 (4.4) 2 (1.9) 13 (13.1) 4 (5.9)  
Mood Disorder 160 (72.4) 241 (81.1) 560 (82.7) 84 (80.8) 65 (65.7) 54 (79.4)  
DAB Disorders 14 (6.3) 8 (2.7) 21 (3.1) 7 (6.7) 3 (3.0) 2 (2.9)  
Developmental 
Disorders 
11 (5.0) 1 (0.3) 3 (0.4) 3 (2.9) 7 (7.1) 0 (0.0)  
Psychotic 
Disorders 
3 (1.4) 5 (1.7) 4 (0.6) 4 (0.3) 1 (1.0) 3 (4.4)  
Other MH 
Disorders 
10 (4.5) 24 (8.1) 59 (8.7) 4 (3.9) 10 (10.1) 5 (7.4)  
Prior AAP Exposure, n (%)  <0.001 
No prior AAP 
exposure 
151 (68.3) 210 (70.7) 475 (70.2) 59 (56.7) 57 (57.6) 30 (44.1)  
Treatment with 
same AAP as 
discharge (index 
admission) 
52 (23.5) 51 (17.2) 171 (11.7) 26 (25.0) 14 (14.1) 20 (29.4)  
Treatment with 
different AAP as 
discharge (index 
admission) 
18 (8.1) 36 (12.1) 31 (4.6) 19 (18.3) 28 (28.3) 18 (26.5)  
Charlson Comorbidity Score (On Index Admission), n (%) 0.38 
0 202 (91.4) 276 (92.9) 626 (92.5) 96 (92.3) 96 (97.0) 66 (97.1)  
1 19 (8.6) 21 (7.1) 51 (7.5) 8 (7.7) 3 (3.0) 2 (2.9)  
2 0 0 0 0 0 0  
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Unadjusted and Adjusted Hazard Ratios of Readmission based on a Cox Proportional Hazards 
Model for Privately-Insured, Female, US Children (2 to 17 years) with an index admission for 
Mental Health Treatment, in database 2010 to 2015 (N=1,467) 
 
*Other AAPs: lurasidone, asenapine, iloperidone, paliperidone, clozapine 
 
Variable Hazard Ratio 
 (95 CIs) 
P-value Hazard Ratios 
(Adjusted) 
p-value 
 
Index Admission, Length of Stay 
(LOS) 
1.0 (0.99, 1.02) 0.88   
Age Group   0.16  
Violated the proportional 
hazards assumption.  Model 
stratified on age, so no 
hazard ratio generated 
 
2-12 years 1.6 (0.83, 3.2) 
13-17 years Reference 
Patient Region 0.65   
Northeast Reference   
Midwest 1.1 (0.62, 1.9)   
West 1.1 (0.66, 1.9)   
South 1.4 (0.76, 2.5)   
MH Diagnosis Category 0.13 0.41 
Anxiety Disorder 0.60 (0.29, 1.2) 0.70 (0.34, 1.5) 
Mood Disorders 0.62 (0.40, 0.97) 0.70 (0.42, 1.0) 
Disruptive or Aggressive Behavior 
Disorders 
0.26 (0.08, 0.87) 0.33 (0.1, 1.1) 
 
Developmental Disorders 0.19 (0.03, 1.4) 0.41 (0.05, 3.1) 
Psychotic Disorders 0 0 
Other MH Disorders Reference Reference 
Prior AAP exposure <0.001 <0.001 
No prior AAP exposure 9.5 (3.1, 29.9) 8.9 (3.7, 21.8) 
Treatment with same AAP as 
discharge (index admission) 
1.7 (0.47, 6.1) 1.6 (0.6, 4.2) 
Treatment with different AAP as 
discharge (index admission) 
Reference Reference 
Discharge Atypical Antipsychotic 
Agent 
0.02 0.035 
Risperidone (Risperdal) Reference Reference 
Quetiapine (Seroquel) 0.59 (0.35, 0.98) 0.52 (0.31, 0.88) 
Aripiprazole (Abilify) 1.1 (0.72, 1.6) 0.99 (0.66, 1.5) 
Ziprasidone (Geodon) 0.57 (0.27, 1.2) 0.63 (0.30, 1.3) 
Olanzapine (Zyprexa) 0.86 (0.44, 1.7) 0.87 (0.44, 1.7) 
Other* 0.30 (0.09, 0.96) 0.39 (0.12, 1.3) 
